Original Article
Etanercept in Children with Polyarticular Juvenile Rheumatoid Arthritis
N Engl J Med 2000; 342:763-769March 16, 2000
- Abstract
Background
We evaluated the safety and efficacy of etanercept, a soluble tumor necrosis factor receptor (p75):Fc fusion protein, in children with polyarticular juvenile rheumatoid arthritis who did not tolerate or had an inadequate response to methotrexate.
Methods
Patients 4 to 17 years old received 0.4 mg of etanercept per kilogram of body weight subcutaneously twice weekly for up to three months in the initial, open-label part of a multicenter trial. Those who responded to treatment then entered a double-blind study and were randomly assigned to receive either placebo or etanercept for four months or until a flare of the disease occurred. A response was defined as an improvement of 30 percent or more in at least three of six indicators of disease activity, with no more than one indicator worsening by more than 30 percent.
Results
At the end of the open-label study, 51 of the 69 patients (74 percent) had had responses to etanercept treatment. In the double-blind study, 21 of the 26 patients who received placebo (81 percent) withdrew because of disease flare, as compared with 7 of the 25 patients who received etanercept (28 percent) (P=0.003). The median time to disease flare with placebo was 28 days, as compared with more than 116 days with etanercept (P<0.001). In the double-blind study, there were no significant differences between the two treatment groups in the frequency of adverse events.
Conclusions
Treatment with etanercept leads to significant improvement in patients with active polyarticular juvenile rheumatoid arthritis. Etanercept is well tolerated by pediatric patients.
Media in This Article
Figure 1
Incidence of 30, 50, and 70 Percent Improvement in the 69 Patients Who Received Etanercept in the Open-Label Study.Figure 2
Kaplan–Meier Analysis of the Time to Disease Flare.Article Activity
- Article
Juvenile rheumatoid arthritis is the most common rheumatic condition in children.1,2 In approximately one third of patients, the disease is controlled with nonsteroidal antiinflammatory drugs and an appropriate program of physical and occupational therapy. The remainder are candidates for more aggressive therapy with antirheumatic drugs.
Methotrexate was shown to have a therapeutic advantage over placebo, with an acceptable safety profile, in a randomized, controlled trial in children with juvenile rheumatoid arthritis who had polyarticular involvement (regardless of the type of onset).3 Long-term studies showed that methotrexate is efficacious and well tolerated in most children with juvenile rheumatoid arthritis.3-6 However, some patients do not have an adequate response to methotrexate, even at doses of up to 1 mg per kilogram of body weight per week.7,8 The frequency and severity of side effects increase with higher doses of methotrexate, and the consequences of long-term use are not known. Exacerbation of disease during treatment with stable doses of methotrexate and the need to increase the methotrexate dose over time suggest that drug resistance to methotrexate may develop.9
Tumor necrosis factor (TNF) is a proinflammatory cytokine that has a complex role in the pathogenesis of rheumatoid arthritis.10-17 TNF is elevated in both the serum and the synovial fluid of children with juvenile rheumatoid arthritis. Serum levels of soluble TNF receptor are elevated in patients with juvenile rheumatoid arthritis (all subtypes), and the level is correlated with disease activity.18 In one study, tumor necrosis factor was detected in 45 percent of samples of synovial fluid from 44 children with juvenile rheumatoid arthritis (all subtypes).19 Further evidence that TNF may amplify local inflammation and lead to joint destruction came from a study in which both TNF and lymphotoxin-α were detected in the majority of synovial-tissue samples from patients with juvenile rheumatoid arthritis.20
Etanercept (Enbrel, Immunex, Seattle), a genetically engineered fusion protein consisting of two identical chains of the recombinant extracellular human TNF-receptor p75 monomer fused with the Fc domain of human IgG1, effectively binds TNF and lymphotoxin-α and inhibits their activity.21,22 Randomized, double-blind, placebo-controlled trials showed that etanercept treatment had significant clinical benefit with minimal toxicity in adults with active rheumatoid arthritis that did not respond to other disease-modifying drugs.23-25 We conducted a randomized, multicenter, double-blind trial of etanercept for the treatment of polyarticular juvenile rheumatoid arthritis in children who did not tolerate or who had an inadequate response to methotrexate.
Methods
Patients
Eligible patients were 4 to 17 years of age and had active polyarticular juvenile rheumatoid arthritis. During the first six months of the disease, some patients had had pauciarticular arthritis (four or fewer joints involved), some had had polyarticular arthritis (five or more joints involved), and some had had systemic arthritis (associated with spiking fever and rheumatoid rash). “Active” polyarticular disease was defined by the presence of five or more swollen joints and three or more joints with limitation of motion and pain, tenderness, or both. Before enrollment, patients had active disease despite treatment with nonsteroidal antiinflammatory drugs and with methotrexate at doses of at least 10 mg per square meter of body-surface area per week. The patients had normal or nearly normal platelet, white-cell, and neutrophil counts, hepatic aminotransferase levels, and results of renal-function tests. Pregnant and lactating patients were excluded, and girls with childbearing potential were required to use contraception throughout the study. Patients with major concurrent medical conditions were also ineligible.
Study Design
An independent review committee at each study site approved the protocol and amendments, and each patient's parent or legal guardian gave written informed consent before the start of the study. A safety monitoring board reviewed adverse events that occurred during the study. Methotrexate was discontinued 14 days and other disease-modifying antirheumatic drugs 28 days before receipt of etanercept. Intraarticular and soft-tissue corticosteroid injections were not permitted during or for one month before the trial. Stable doses of nonsteroidal antiinflammatory drugs, low doses of corticosteroids (≤0.2 mg of prednisone per kilogram per day, with a maximum of 10 mg per day), or both were permitted. Pain medications were allowed except during the 12 hours before a joint assessment.
Vials of study medication contained either 25 mg of lyophilized etanercept (for both parts of the study) or placebo (for the double-blind study). Before injection, study-site staff who were not involved in patient assessments reconstituted the contents with 1 ml of bacteriostatic water containing 0.9 percent benzyl alcohol.
All patients received 0.4 mg of etanercept per kilogram (maximum, 25 mg) subcutaneously twice weekly for up to three months in the open-label part of the trial. At the end of the third month, patients whose condition had improved according to the definition of Giannini et al.26 were randomly assigned to receive either placebo or 0.4 mg of etanercept per kilogram subcutaneously twice weekly in the double-blind study (months 4 through 7) until disease flare occurred or four months elapsed, whichever was earlier. Efficacy was assessed according to the number of patients with disease flare after receipt of placebo or etanercept.
Physical examinations, measures of disease activity, and laboratory tests (hematologic analysis, serum chemical analysis, and urinalysis) were performed at screening and repeated on day 1 (before the administration of etanercept or placebo) and day 15 and at the end of each month during the study. Final safety assessments were made 30 days after the discontinuation of the study drug for patients who withdrew from the study or did not continue to the double-blind study, or at the patient's next scheduled visit if the patient withdrew from the study because of disease flare. Serum was obtained at screening and at the end of months 3 and 7 for testing for autoantibodies (antinuclear antibodies, antibodies to double-stranded DNA, IgG and IgM anticardiolipin antibodies, and antibodies to extractable nuclear antigens), and on day 1 before the administration of the study drug and at the end of months 3 and 7 for testing for antibodies to etanercept.
Definition of Improvement
The definition of improvement used to assess disease response employs a core set of six response variables: global assessment of the severity of disease by the physician, global assessment of overall well-being by the patient or parent, number of “active” joints (joints with swelling not due to deformity or joints with limitation of motion and with pain, tenderness, or both), number of joints with limitation of motion, functional ability, and erythrocyte sedimentation rate.26,27 In this study, the fourth measure was modified to the “number of joints with limitation of motion and with pain, tenderness, or both” so as to eliminate counting joints with contractures that might not have improved during the short course of treatment.
To meet the definition of improvement at a scheduled visit or at the end of month 3, patients had to have a 30 percent improvement from base line in at least three of the six response variables. They could also have worsening of 30 percent or more in no more than one of the six response variables. Additional assessments of disease activity included the articular severity score,28 duration of morning stiffness, degree of pain (on a visual-analogue scale), and C-reactive protein levels. Patients were also evaluated for 50 percent and 70 percent improvement (50 percent and 70 percent improvement in at least three of the six response variables and a worsening of 30 percent or more in no more than one of the six response variables).
The primary efficacy end point, which was evaluated in the double-blind study, was the number of patients with disease flare. The definition of disease flare created specifically for this pediatric trial was based on the change in the core set of response variables from the beginning of the double-blind study. Patients who met the criteria for disease flare had worsening of 30 percent or more in three of the six response variables and a minimum of two active joints. They also could have improvement of 30 percent or more in no more than one of the six response variables. Global assessments, if used to define flare, had to change by at least 2 units on a scale from 0 to 10.
Statistical Analysis
A blocked randomization scheme with stratification according to study center and number of active joints (≤2 vs. >2) at the end of month 3 (in the open-label study) was used to assign patients to placebo or etanercept in the double-blind study.
In the double-blind study, base-line and demographic characteristics were compared between treatment groups by the Wilcoxon rank-sum test and the likelihood-ratio chi-square test. Laboratory results were summarized separately from adverse events according to a modification of the National Cancer Institute Common Toxicity Criteria and the testing laboratory's normal ranges. Comparisons of shifts in laboratory values (to below normal, normal, or above normal) were made with use of the Stuart–Maxwell chi-square test.29
The percentages of patients with a response to therapy who had disease flare while receiving placebo or etanercept in the double-blind study were compared by Mantel–Haenszel methods.30 Patients who withdrew early without disease flare were counted in the analysis with those who continued to have a response.
To evaluate any bias introduced by the withdrawal assumption in the primary analysis, an analysis of time to flare (by the log-rank test) was undertaken in which data on patients who withdrew without flare were censored at the time of withdrawal. The effect of base-line characteristics on flare rates was assessed by main-effects logistic regression. The percentages of patients with a response who continued to have a response after receiving etanercept or placebo in the double-blind study were compared by Mantel–Haenszel methods. All tests were two-sided, with a significance level of 0.05.
In all summaries of measures of disease activity, a last-observation-carried-forward approach was used for missing data or visits and for patients who withdrew early.
Results
Base-Line Characteristics
The base-line demographic and disease characteristics of the study patients are summarized in Table 1Table 1
Demographic Characteristics and Disease History.. Forty-three female and 26 male patients were enrolled in the open-label study; of these, 34 female and 17 male patients continued to the double-blind study. At enrollment, the mean age was 10.5 years (range, 4 to 17) and the mean duration of juvenile rheumatoid arthritis was 5.9 years. The groups were well balanced in the double-blind study, except for age group and race (P<0.02) and corticosteroid use at base line (P=0.05). The unequal randomization did not affect the study results.Sixty-four of the 69 patients enrolled in part 1 (93 percent) completed treatment. Early discontinuations were due to an adverse event in one patient who had urticaria with the first dose of etanercept, refusal of treatment by two patients, and lack of response in two patients. Of the 25 patients in the etanercept group in the double-blind trial, 19 (76 percent) completed treatment and 6 withdrew because of disease flare. Seven of the 26 patients in the placebo group (27 percent) completed the study; 1 withdrew because of parental refusal to allow continuation, and 18 withdrew because of disease flare.
Disease Response (Open-Label Study)
Fifty-one of the 69 patients enrolled in the open-label study (74 percent) met the definition of improvement at the end of that study. Considerable improvements in all measures of disease activity were seen with etanercept, and improvement was noted in patients as early as the first evaluation, two weeks after the beginning of treatment (Table 2Table 2
Measures of Disease Activity and Improvement from Base Line.). Forty-four of the 69 patients (64 percent) met the definition of 50 percent improvement, and 25 (36 percent) met the definition of 70 percent improvement at the end of the open-label study (Figure 1Figure 1Incidence of 30, 50, and 70 Percent Improvement in the 69 Patients Who Received Etanercept in the Open-Label Study.).Efficacy (Double-Blind Study)
Disease Flare
In the double-blind study, significantly more patients who received placebo (21 of 26 [81 percent]) than patients who received etanercept (7 of 25 [28 percent], P=0.003) had disease flare. The rates of flare remained consistently and significantly lower in the etanercept group (P<0.001) after adjustment for the effects of base-line characteristics (Table 3Table 3
Incidence of Disease Flare in the Double-Blind Study According to the Base-Line Characteristics of the Patients.). With the exception of corticosteroid use at base line (P= 0.05), none of the base-line characteristics were significant predictors of flare rates (P>0.15) (Table 3).The median time to flare was more than 116 days for patients who received etanercept and 28 days for patients who received placebo (P<0.001) (Figure 2Figure 2
Kaplan–Meier Analysis of the Time to Disease Flare.). Because 13 of 25 patients were still receiving etanercept at the end of the study (day 116) without disease flare, the median time to flare was greater than 116 days.Disease Response at End of Study
The definition of improvement was based on changes from base-line values, whereas disease flare was based on changes from values at the time of randomization to either etanercept or placebo in the double-blind study. Depending on the magnitude of a patient's response in the open-label study, response to treatment and presence of disease flare were not mutually exclusive outcomes. For example, if a patient had 28 active joints at base line but only 2 active joints at the time of randomization, a change to 3 active joints would be considered a flare (at least 30 percent worse than the condition at the time of randomization) but would also still be considered improvement (at least 30 percent improved from base line). At the end of the seven-month study, 20 of the 25 patients who received etanercept in the double-blind study (80 percent) still met the definition of improvement, as compared with 9 of the 26 patients who received placebo (35 percent, P<0.01).
At the end of the study, 72 percent of the patients who received etanercept (18 patients) and 23 percent of those who received placebo (6 patients) met the definition of 50 percent improvement. Forty-four percent of the patients who received etanercept (11 patients) and 19 percent of those who received placebo (5 patients) met the definition of 70 percent improvement. Measures of disease activity continued to improve in patients who received etanercept in the double-blind study, whereas disease activity increased in those who received placebo (Table 2).
Scores in the disability domain of the Childhood Health Assessment Questionnaire31,32 (a measure of the patient's physical functional ability) began to improve at the first evaluation two weeks after the beginning of etanercept treatment. At the end of the open-label study, a 37 percent median improvement in scores was seen for all patients. In the double-blind study, a 54 percent median improvement in scores from base line was seen in patients who continued to receive etanercept, as compared with no change from base line in patients who received placebo (P=0.01).
In a significant proportion of patients, there were shifts from elevated values at base line to normal values of C-reactive protein, erythrocyte sedimentation rate, and white-cell and platelet counts after treatment with etanercept in the open-label study (P<0.03 for each variable). In the double-blind study as compared with the end of the open-label study, a significant proportion of patients who received placebo had shifts from normal levels of C-reactive protein and erythrocyte sedimentation rates to above-normal values (P≤ 0.03 for each variable).
Safety
Etanercept was safe and well tolerated. There were no deaths. One patient withdrew because of urticaria after the first dose of etanercept; the urticaria responded to oral antihistamines. This patient later received commercially available etanercept without recurrence of urticaria. Two patients who received etanercept were hospitalized for serious adverse events (one for depression and a personality disorder and one for gastroenteritis–flu syndrome). All other adverse events were of mild-to-moderate intensity.
In the open-label study, the most common adverse events were injection-site reactions (39 percent of patients), upper respiratory tract infections (35 percent), headache (20 percent), rhinitis (16 percent), abdominal pain (16 percent), vomiting (14 percent), pharyngitis (14 percent), nausea (12 percent), gastrointestinal infection (12 percent), and rash (10 percent).
In the double-blind study, there were no significant differences in the frequencies of adverse events between patients who received etanercept and those who received placebo. Injection-site reactions occurred in one patient in each of the treatment groups in the double-blind study. There were no laboratory abnormalities requiring urgent treatment in the etanercept group. No patient had persistent elevations in autoantibodies or had signs or symptoms of another autoimmune disease. Two patients tested positive for non-neutralizing antibody to etanercept. Fifty-nine of the 68 eligible patients in the study chose to continue treatment in an open-label, extended-treatment study.
Discussion
The choice of a second-line agent for the treatment of juvenile rheumatoid arthritis has become more difficult because placebo-controlled trials and long-term prospective studies in children with juvenile rheumatoid arthritis have shown a lack of efficacy of agents commonly used in adults.33-37 Methotrexate is not efficacious or well tolerated in some patients with juvenile rheumatoid arthritis, and higher doses of methotrexate may be associated with greater toxicity.7
The design of this double-blind, placebo-controlled trial was sensitive to the problems of the population of patients with severe juvenile rheumatoid arthritis, for whom few treatment options are available. The study design allowed all patients to try the new treatment; only those who had a response to treatment were enrolled in the randomized portion of the trial. In addition, the definition of disease flare did not require the disease to become as severe as at base line. The protocol allowed patients to discontinue the study immediately after disease flare and be treated with etanercept in an open-label, long-term program. With the definition of disease flare used in this study, we effectively demonstrated differences in flare rates between the treatment groups.
The dose of etanercept used in this study (0.4 mg per kilogram) provided a favorable risk–benefit profile in children with polyarticular juvenile rheumatoid arthritis. Adverse events were of the types and intensity seen in a general pediatric population. There were no life-threatening adverse events, and the events were self-limited. A continued response was documented in patients who received etanercept in the double-blind study. At the end of the study, 80 percent of the patients who received etanercept for seven months met the definition of 30 percent improvement, as compared with 35 percent of the patients who received etanercept for three months and placebo for up to four months.
The results of this study confirm that TNF, lymphotoxin-α, or both have a role in juvenile rheumatoid arthritis, and that inhibition of these substances is a valid therapeutic intervention. Etanercept was effective in pediatric patients with severe polyarticular juvenile rheumatoid arthritis (regardless of the type of onset) who did not tolerate or have an adequate response to methotrexate. The significant clinical response supports the use of etanercept in children with juvenile rheumatoid arthritis.
Supported by Immunex Corporation, Seattle, which provided the study drug and grants to investigational sites, by the Children's Hospital Foundation of Cincinnati, and by grants from the National Institutes of Health (AR42632 and AR44059-P60 MAMDC).
Drs. Lovell and Giannini have served as ad hoc consultants to Immunex.
We are indebted to the following members of the Pediatric Rheumatology Collaborative Study Group, who served as investigators at the clinical sites and made critically important contributions to this study: Bram Bernstein, M.D., Ronald Laxer, M.D., Judyann Olson, M.D., Ann Marie Reed, M.D., Rayfel Schneider, M.B., B.Ch., Bracha Shaham, M.D., David Sherry, M.D., and Brian Feldman, M.D.; to Jeffrey Siegel, M.D., and Lisa Rider, M.D., at the Food and Drug Administration for assistance in designing the protocol; to clinical research associates Lawrence Soffes and Kate Flanders at Immunex Corporation; to study-site coordinators Nikki Bradford, Sophie Costilla, Karen Felty, Trudy Leicht, Mark Massanari, Josee Quenneville, Kathy Salmonson, Janalee Taylor, Edna Williams, and Diann Wingert; and to Orysia V. Lutz for editorial assistance.
Source Information
From Children's Hospital Medical Center, Cincinnati (D.J.L., E.H.G.); Children's Hospital of Los Angeles, Los Angeles (A.R.); All Children's Hospital, St. Petersburg, Fla. (G.D.C.); the Hospital for Sick Children, Toronto (E.D.S.); the Medical College of Wisconsin, Milwaukee (J.J.N.); the University of North Carolina, Chapel Hill (L.D.S.); Children's Hospital, New Orleans (A.G.); Schneider Children's Hospital, New Hyde Park, N.Y. (N.T.I.); Children's Hospital and Medical Center, Seattle (C.A.W.); and Immunex Corporation, Seattle (J.W., B.K.F.).
Address reprint requests to Dr. Lovell at Children's Hospital Medical Center, Pavilion Bldg. 2-129, 3333 Burnet Ave., Cincinnati, OH 45229-3039.
- References
References
1
Peterson LS ,Mason T ,Nelson AM ,O'Fallon WM ,Gabriel SE . Juvenile rheumatoid arthritis in Rochester, Minnesota 1960-1993: is the epidemiology changing? Arthritis Rheum 1996;39:1385-1390
CrossRef | Web of Science | Medline2
Petty RE ,Malleson P . Epidemiology of juvenile rheumatoid arthritis. World Pediatr Child Care 1987;3:205-2103
Giannini EH ,Brewer EJ ,Kuzmina N , et al. Methotrexate in resistant juvenile rheumatoid arthritis: results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. N Engl J Med 1992;326:1043-1049
Full Text | Web of Science | Medline4
Giannini EH ,Newman AJ ,Fink CW . Low-dose methotrexate in children with JRA: results of a post-trial, long-term follow-up program. Arthritis Rheum 1993;36:Suppl:S54-S54 abstract.
Web of Science5
Graham LD ,Myones BL ,Rivas-Chacon RF ,Pachman LM . Morbidity associated with long-term methotrexate therapy in juvenile rheumatoid arthritis. J Pediatr 1992;120:468-473
CrossRef | Web of Science | Medline6
Halle F ,Prieur AM . Evaluation of methotrexate in the treatment of juvenile chronic arthritis according to the subtype. Clin Exp Rheumatol 1991;9:297-302
Web of Science | Medline7
Wallace CA ,Sherry DD . Preliminary report of higher dose methotrexate treatment in juvenile rheumatoid arthritis. J Rheumatol 1992;19:1604-1607
Web of Science | Medline8
Reiff A ,Shaham B ,Wood BP ,Bernstein BH ,Stanley P ,Szer IS . High dose methotrexate in the treatment of refractory juvenile rheumatoid arthritis. Clin Exp Rheumatol 1995;13:113-118
Web of Science | Medline9
Wallace CA . The use of methotrexate in childhood rheumatic diseases. Arthritis Rheum 1998;41:381-391
CrossRef | Web of Science | Medline10
Thornton SC ,Por SB ,Penny R ,Richter M ,Shelley L ,Breit SN . Identification of the major fibroblast growth factors released spontaneously in inflammatory arthritis as platelet derived growth factor and tumour necrosis factor-alpha. Clin Exp Immunol 1991;86:79-86
CrossRef | Web of Science | Medline11
Dayer JM ,Beutler B ,Cerami A . Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 1985;162:2163-2168
CrossRef | Web of Science | Medline12
Bertolini DR ,Nedwin GE ,Bringman TS ,Smith DD ,Mundy GR . Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 1986;319:516-518
CrossRef | Web of Science | Medline13
Saklatvala J . Tumour necrosis factor α stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 1986;322:547-549
CrossRef | Web of Science | Medline14
von Asmuth EJU ,van der Linden CJ ,Leeuwenberg JFM ,Buurman WA . Involvement of the CD11b/CD18 integrin, but not of the endothelial cell adhesion molecules ELAM-1 and ICAM-1 in tumor necrosis factor-α-induced neutrophil toxicity. J Immunol 1991;147:3869-3875
Web of Science | Medline15
Beckham JC ,Caldwell DS ,Peterson BL , et al. Disease severity in rheumatoid arthritis: relationships of plasma tumor necrosis factor-α, soluble interleukin 2-receptor, soluble CD4/CD8 ratio, neopterin, and fibrin D-dimer to traditional severity and functional measures. J Clin Immunol 1992;12:353-361
CrossRef | Web of Science | Medline16
Brennan FM ,Chantry D ,Jackson A ,Maini R ,Feldmann M . Inhibitory effect of TNFα antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989;2:244-247
CrossRef | Web of Science | Medline17
Saez-Llorens X ,Jafari HS ,Olsen KD ,Nariuchi H ,Hansen EJ ,McCracken GH Jr . Induction of suppurative arthritis in rabbits by Haemophilus endotoxin, tumor necrosis factor-α, and interleukin-1 β. J Infect Dis 1991;163:1267-1272
CrossRef | Web of Science | Medline18
Mangge H ,Kenzian H ,Gallistl S , et al. Serum cytokines in juvenile rheumatoid arthritis: correlation with conventional inflammation parameters and clinical subtypes. Arthritis Rheum 1995;38:211-220
CrossRef | Web of Science | Medline19
Eberhard BA ,Laxer RM ,Andersson U ,Silverman ED . Local synthesis of both macrophage and T cell cytokines by synovial fluid cells from children with juvenile rheumatoid arthritis. Clin Exp Immunol 1994;96:260-266
CrossRef | Web of Science | Medline20
Grom AA ,Murray KJ ,Luyrink L , et al. Patterns of expression of tumor necrosis factor α, tumor necrosis factor β, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondyloarthropathy. Arthritis Rheum 1996;39:1703-1710
CrossRef | Web of Science | Medline21
Mohler KM ,Sleath PR ,Fitzner JN , et al. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 1994;370:218-220
CrossRef | Web of Science | Medline22
Mohler KM ,Torrance DS ,Smith CA , et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993;151:1548-1561
Web of Science | Medline23
Moreland LW ,Baumgartner SW ,Schiff MH , et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-147
Full Text | Web of Science | Medline24
Moreland LW ,Schiff MH ,Baumgartner SW , et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999;130:478-486
Web of Science | Medline25
Weinblatt ME ,Kremer JM ,Bankhurst AD , et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-259
Full Text | Web of Science | Medline26
Giannini EH ,Ruperto N ,Ravelli A ,Lovell DJ ,Felson DT ,Martini A . Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-1209
CrossRef | Web of Science | Medline27
Giannini EH ,Lovell DJ ,Felson DT ,Goldsmith CH . Preliminary core set of outcome variables for use in JRA clinical trials. Arthritis Rheum 1994;37:Suppl:S428-S428 abstract.
CrossRef | Web of Science28
Giannini EH ,Cassidy JT . Methotrexate in juvenile rheumatoid arthritis: do the benefits outweigh the risks? Drug Saf 1993;9:325-339
CrossRef | Web of Science | Medline29
Stuart A . A test for homogeneity of the marginal distributions in a two-way classification. Biometrika 1955;42:412-416
Web of Science30
Mehta CR ,Walsh SJ . Comparison of exact, mid-p, and Mantel-Haenszel confidence intervals for the common odds ratio across several 2 x 2 contingency tables. Am Stat 1992;46:146-150
CrossRef | Web of Science31
Singh G ,Athreya BH ,Fries JF ,Goldsmith DP . Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum 1994;37:1761-1769
CrossRef | Web of Science | Medline32
Ramey DR ,Raynauld JP ,Fries JF . The Health Assessment Questionnaire 1992: status and review. Arthritis Care Res 1992;5:119-129
CrossRef | Medline33
Brewer EJ ,Giannini EH ,Kuzmina N ,Alekseev L . Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis: results of the U.S.A.-U.S.S.R. double-blind placebo-controlled trial. N Engl J Med 1986;314:1269-1276
Full Text | Web of Science | Medline34
Giannini EH ,Brewer EJ ,Kuzmina N ,Alekseev L ,Shokh BP . Characteristics of responders and nonresponders to slow-acting antirheumatic drugs in juvenile rheumatoid arthritis. Arthritis Rheum 1988;31:15-20
CrossRef | Web of Science | Medline35
Giannini EH ,Brewer EJ Jr ,Kuzmina N ,Shaikov A ,Wallin B . Auranofin in the treatment of juvenile rheumatoid arthritis: results of the USA-USSR double-blind, placebo-controlled trial. Arthritis Rheum 1990;33:466-476
CrossRef | Web of Science | Medline36
Giannini EH ,Barron KS ,Spencer CH , et al. Auranofin therapy for juvenile rheumatoid arthritis: results of the five-year open label extension trial. J Rheumatol 1991;18:1240-1242
Web of Science | Medline37
Silverman ED ,Giannini EH ,Cawkwell G . Intravenous immune globulin in systemic JRA: results of a randomized controlled trial. Arthritis Rheum 1993;36:Suppl:S59-S59 abstract.
CrossRef | Web of Science
- Citing Articles (330)
Citing Articles
1
Shabina Habibi, Athimalaipet V Ramanan. (2012) Review of biologics in children with rheumatic diseases. International Journal of Clinical Rheumatology 7:1, 81-93
CrossRef2
Masaaki Mori, Syuji Takei, Tomoyuki Imagawa, Hiroyuki Imanaka, Yasuhito Nerome, Rumiko Higuchi, Yoshifumi Kawano, Shumpei Yokota, Noriko Sugiyama, Hirotoshi Yuasa, Tracey Fletcher, Joseph S. Wajdula. (2012) Safety and efficacy of long-term etanercept in the treatment of methotrexate-refractory polyarticular-course juvenile idiopathic arthritis in Japan. Modern Rheumatology
CrossRef3
R. Gurion, T. J. A. Lehman, L. N. Moorthy. (2012) Systemic Arthritis in Children: A Review of Clinical Presentation and Treatment. International Journal of Inflammation 2012, 1-16
CrossRef4
Andreas Reiff. (2012) Treatment of Systemic Juvenile Idiopathic Arthritis with Tocilizumab - the Role of Anti-Interleukin-6 Therapy After a Decade of Treatment. Biologics in Therapy 2:1,
CrossRef5
A. Kelly, A.V. Ramanan. (2011) The principles of pharmacological treatment of juvenile idiopathic arthritis. Paediatrics and Child Health 21:12, 563-568
CrossRef6
Gerald Gartlehner. (2011) Quantifying the unquantifiable. Journal of Clinical Epidemiology
CrossRef7
Gregory A. Yanik, Shin Mineishi, John E. Levine, Carrie L. Kitko, Eric S. White, Mark T. Vander Lugt, Andrew C. Harris, Thomas Braun, Kenneth R. Cooke. (2011) Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for Sub-Acute Pulmonary Dysfunction Following Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation
CrossRef8
Alberto Martini. (2011) Maladie de Still de l’enfant, évolution conceptuelle et thérapeutique. Revue du Rhumatisme Monographies
CrossRef9
Oguz Durmus, Levent Tekin, Alparslan Bayram Carli, Engin Cakar, Ali Acar, Asim Ulcay, Umit Dincer, Mehmet Zeki Kiralp. (2011) Hepatitis B virus reactivation in a Juvenile Rheumatoid arthritis patient under treatment and its successful management: a complicated case. Rheumatology International
CrossRef10
Todd A Kerensky, Alice B Gottlieb, Shimrat Yaniv, Shiu-chung Au. (2011) Etanercept: efficacy and safety for approved indications. Expert Opinion on Drug Safety1-19
CrossRef11
P. Quartier. (2011) Nouveaux traitements en rhumatologie pédiatrique : impact, limites et perspectives. Archives de Pédiatrie 18:11, 1218-1223
CrossRef12
Remi Ozawa, Yutaka Inaba, Masaaki Mori, Ryoki Hara, Masako Kikuchi, Rumiko Higuchi, Takako Miyamae, Tomoyuki Imagawa, Takeo Fujiwara, Tomoyuki Saito, Shumpei Yokota. (2011) Definitive differences in laboratory and radiological characteristics between two subtypes of juvenile idiopathic arthritis: systemic arthritis and polyarthritis. Modern Rheumatology
CrossRef13
Benjamin I. Goldstein, Katelyn A. Collinger, Francis Lotrich, Anna L. Marsland, Mary-Kay Gill, David A. Axelson, Boris Birmaher. (2011) Preliminary Findings Regarding Proinflammatory Markers and Brain-Derived Neurotrophic Factor Among Adolescents with Bipolar Spectrum Disorders. Journal of Child and Adolescent Psychopharmacology 21:5, 479-484
CrossRef14
Sylvain Breton, Sandrine Jousse-Joulin, Claire Cangemi, Loic de Parscau, Danielle Colin, Luc Bressolette, Alain Saraux, Valérie Devauchelle-Pensec. (2011) Comparison of Clinical and Ultrasonographic Evaluations for Peripheral Synovitis in Juvenile Idiopathic Arthritis. Seminars in Arthritis and Rheumatism 41:2, 272-278
CrossRef15
Hans-Iko Huppertz, Dirk Föll, Hermann Girschick, Kirsten Minden, Gerd Horneff. (2011) Progress in pediatric rheumatology: apprehend the opportunities of the future without forgetting the lessons from the past. Rheumatology International 31:10, 1259-1262
CrossRef16
Gregor Dueckers, Nihal Guellac, Martin Arbogast, Guenther Dannecker, Ivan Foeldvari, Michael Frosch, Gerd Ganser, Arnd Heiligenhaus, Gerd Horneff, Arnold Illhardt, Ina Kopp, Ruediger Krauspe, Barbara Markus, Hartmut Michels, Matthias Schneider, Wolfram Singendonk, Helmut Sitter, Marianne Spamer, Norbert Wagner, Tim Niehues. (2011) Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis. Clinical Immunology
CrossRef17
P. Woo, R. E. Petty. (2011) Looking at paediatric rheumatology over the past 50 years. Rheumatology 50:9, 1533-1536
CrossRef18
Ellen Nordal, Marek Zak, Kristiina Aalto, Lillemor Berntson, Anders Fasth, Troels Herlin, Pekka Lahdenne, Susan Nielsen, Bjørn Straume, Marite Rygg, . (2011) Ongoing disease activity and changing categories in a long-term nordic cohort study of juvenile idiopathic arthritis. Arthritis & Rheumatism 63:9, 2809-2818
CrossRef19
Nicolino Ruperto, Alberto Martini. (2011) Emerging drugs to treat juvenile idiopathic arthritis. Expert Opinion on Emerging Drugs 16:3, 493-505
CrossRef20
Gopinath Sutendra, Peter Dromparis, Sébastien Bonnet, Alois Haromy, Michael S. McMurtry, R. Chris Bleackley, Evangelos D. Michelakis. (2011) Pyruvate dehydrogenase inhibition by the inflammatory cytokine TNFα contributes to the pathogenesis of pulmonary arterial hypertension. Journal of Molecular Medicine 89:8, 771-783
CrossRef21
K. Sevcic, I. Orban, V. Brodszky, A. Bazso, Z. Balogh, G. Poor, E. Kiss. (2011) Experiences with tumour necrosis factor- inhibitors in patients with juvenile idiopathic arthritis: Hungarian data from the National Institute of Rheumatology and Physiotherapy Registry. Rheumatology 50:7, 1337-1340
CrossRef22
Carol A. Wallace, Edward H. Giannini, Bin Huang, Lukasz Itert, Nicolino Ruperto, , , . (2011) American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care & Research 63:7, 929-936
CrossRef23
Tomoyuki Imagawa, Shumpei Yokota, Masaaki Mori, Takako Miyamae, Syuji Takei, Hiroyuki Imanaka, Yasuhito Nerome, Naomi Iwata, Takuji Murata, Mari Miyoshi, Norihiro Nishimoto, Tadamitsu Kishimoto. (2011) Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis. Modern Rheumatology
CrossRef24
Flora B. de Waard-van der Spek, Lisette W. A. van Suijlekom-Smit, Arnold P. Oranje. 2011. Psoriasis: Treatments. , 82.1-82.7.
CrossRef25
Polly Livermore, Clarissa Pilkington. 2011. The Use of Emerging Biological Treatments in Children. , 182.1-182.15.
CrossRef26
F. H. M. Prince, E. W. de Bekker-Grob, M. Twilt, M. A. J. van Rossum, E. P. A. H. Hoppenreijs, R. ten Cate, Y. Koopman-Keemink, S. L. Gorter, H. Raat, L. W. A. van Suijlekom-Smit. (2011) An analysis of the costs and treatment success of etanercept in juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children register. Rheumatology 50:6, 1131-1136
CrossRef27
Berent Prakken, Salvatore Albani, Alberto Martini. (2011) Juvenile idiopathic arthritis. The Lancet 377:9783, 2138-2149
CrossRef28
Michael W. Beresford. (2011) Juvenile Idiopathic Arthritis. Pediatric Drugs 13:3, 161-173
CrossRef29
Gerd Horneff. (2011) Treatment options with biologics for juvenile idiopathic arthritis. International Journal of Clinical Rheumatology 6:3, 305-323
CrossRef30
Christian Renaud, Philippe Ovetchkine, Patricia Bortolozzi, Claire Saint-Cyr, Bruce Tapiero. (2011) Fatal group A Streptococcus purpura fulminans in a child receiving TNF-α blocker. European Journal of Pediatrics 170:5, 657-660
CrossRef31
Martin Aringer, Josef S. Smolen. (2011) Therapeutic blockade of TNF in patients with SLE—Promising or crazy?. Autoimmunity Reviews
CrossRef32
JCF van Luijn, M Danz, JWJ Bijlsma, FWJ Gribnau, HGM Leufkens. (2011) Post-approval trials of new medicines: widening use or deepening knowledge? Analysis of 10 years of etanercept. Scandinavian Journal of Rheumatology 40:3, 183-191
CrossRef33
Thao Pham, Hervé Bachelez, Jean-Marie Berthelot, Jacques Blacher, Yoram Bouhnik, Pascal Claudepierre, Arnaud Constantin, Bruno Fautrel, Philippe Gaudin, Vincent Goëb, Laure Gossec, Philippe Goupille, Séverine Guillaume-Czitrom, Eric Hachulla, Isabelle Huet, Denis Jullien, Odile Launay, Marc Lemann, Jean-Francis Maillefert, Jean-Pierre Marolleau, Valérie Martinez, Charles Masson, Jacques Morel, Luc Mouthon, Stanislas Pol, Xavier Puéchal, Pascal Richette, Alain Saraux, Thierry Schaeverbeke, Martin Soubrier, Anne Sudre, Tu-Anh Tran, Manuelle Viguier, Olivier Vittecoq, Daniel Wendling, Xavier Mariette, Jean Sibilia. (2011) TNF alpha antagonist therapy and safety monitoring. Joint Bone Spine 78, 15-185
CrossRef34
Masaaki Mori, Syuji Takei, Tomoyuki Imagawa, Hiroyuki Imanaka, Yasuhito Nerome, Rumiko Kurosawa, Yoshifumi Kawano, Shumpei Yokota, Noriko Sugiyama, Hirotoshi Yuasa, Tracey Fletcher, Joseph S. Wajdula. (2011) Etanercept in the treatment of disease-modifying anti-rheumatic drug (DMARD)-refractory polyarticular course juvenile idiopathic arthritis: experience from Japanese clinical trials. Modern Rheumatology
CrossRef35
Timothy Beukelman, Nivedita M. Patkar, Kenneth G. Saag, Sue Tolleson-Rinehart, Randy Q. Cron, Esi Morgan DeWitt, Norman T. Ilowite, Yukiko Kimura, Ronald M. Laxer, Daniel J. Lovell, Alberto Martini, C. Egla Rabinovich, Nicolino Ruperto. (2011) 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care & Research 63:4, 465-482
CrossRef36
2011. Specific Therapeutic Agents. , 205-317.
CrossRef37
Luciana Breda, Marianna Torto, Sara Sanctis, Francesco Chiarelli. (2011) Biologics in children’s autoimmune disorders: efficacy and safety. European Journal of Pediatrics 170:2, 157-167
CrossRef38
Wendy J. Ungar, Vania Costa, Rebecca Hancock-Howard, Brian M. Feldman, Ronald M. Laxer. (2011) Cost-effectiveness of biologics in polyarticular-course juvenile idiopathic arthritis patients unresponsive to disease-modifying antirheumatic drugs. Arthritis Care & Research 63:1, 111-119
CrossRef39
T. R. Southwood, H. E. Foster, J. E. Davidson, K. L. Hyrich, C. B. Cotter, L. R. Wedderburn, R. G. Hull, H. E. Venning, J. K. Rahman, C. L. Cummins, . (2011) Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients. Rheumatology 50:1, 189-195
CrossRef40
G. Horneff, I. Foeldvari, K. Minden, D. Moebius, T. Hospach. (2011) Report on malignancies in the German juvenile idiopathic arthritis registry. Rheumatology 50:1, 230-236
CrossRef41
Norman T. Ilowite, Ronald M. Laxer. 2011. PHARMACOLOGY AND DRUG THERAPY. , 71-126.
CrossRef42
Fabrizio De Benedetti, Rayfel Schneider. 2011. SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS. , 236-248.
CrossRef43
Hermine I. Brunner, Edward H. Giannini. 2011. TRIAL DESIGN, MEASUREMENT, AND ANALYSIS OF CLINICAL INVESTIGATIONS. , 127-156.
CrossRef44
V. Papsdorf, G. Horneff. (2011) Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis. Rheumatology 50:1, 214-221
CrossRef45
G. Dückers, T. Niehues. (2011) Rheuma bei Kindern und Jugendlichen. Monatsschrift Kinderheilkunde 159:1, 25-33
CrossRef46
Ciarán M. Duffy, Brian M. Feldman. 2011. ASSESSMENT OF HEALTH STATUS, FUNCTION, AND QUALITY OF LIFE OUTCOMES. , 157-167.
CrossRef47
Nadine F. Choueiter, Aaron K. Olson, Danny D. Shen, Michael A. Portman. (2010) Prospective Open-Label Trial of Etanercept as Adjunctive Therapy for Kawasaki Disease. The Journal of Pediatrics 157:6, 960-966.e1
CrossRef48
Pierre Quartier. (2010) Current treatments for juvenile idiopathic arthritis. Joint Bone Spine 77:6, 511-516
CrossRef49
Susan Shenoi, Carol A. Wallace. (2010) Tumor Necrosis Factor Inhibitors in the Management of Juvenile Idiopathic Arthritis. Pediatric Drugs 12:6, 367-377
CrossRef50
Edward H. Giannini, Norman T. Ilowite, Daniel J. Lovell, Carol A. Wallace, C. Egla Rabinovich, Andreas Reiff, Gloria Higgins, Beth Gottlieb, , Yun Chon, Nan Zhang, Scott W. Baumgartner. (2010) Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis. Arthritis & Rheumatism 62:11, 3259-3264
CrossRef51
Nicolino Ruperto, Daniel J. Lovell, Tracy Li, Flavio Sztajnbok, Claudia Goldenstein-Schainberg, Morton Scheinberg, Inmaculada Calvo Penades, Michael Fischbach, Javier Orozco Alcala, Philip J. Hashkes, Christine Hom, Lawrence Jung, Loredana Lepore, Sheila Oliveira, Carol Wallace, Maria Alessio, Pierre Quartier, Elisabetta Cortis, Anne Eberhard, Gabriele Simonini, Irene Lemelle, Elizabeth Candell Chalom, Leonard H. Sigal, Alan Block, Allison Covucci, Marleen Nys, Alberto Martini, Edward H. Giannini. (2010) Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis. Arthritis Care & Research 62:11, 1542-1551
CrossRef52
Ukihide Tateishi, Tomoyuki Imagawa, Noriko Kanezawa, Tetsuhiko Okabe, Kazuya Shizukuishi, Tomio Inoue, Shumpei Yokota. (2010) PET assessment of disease activity in children with juvenile idiopathic arthritis. Pediatric Radiology 40:11, 1781-1788
CrossRef53
Nicolino Ruperto, Edward H. Giannini, Angela Pistorio, Hermine I. Brunner, Alberto Martini, Daniel J. Lovell. (2010) Is it time to move to active comparator trials in juvenile idiopathic arthritis?: A review of current study designs. Arthritis & Rheumatism 62:11, 3131-3139
CrossRef54
G. Horneff. (2010) Juvenile Arthritiden. Zeitschrift für Rheumatologie 69:8, 719-737
CrossRef55
Philip J. Hashkes, Yosef Uziel, Ronald M. Laxer. (2010) The safety profile of biologic therapies for juvenile idiopathic arthritis. Nature Reviews Rheumatology 6:10, 561-571
CrossRef56
Keith C. Meyer, Catherine Decker, Robert Baughman. (2010) Toxicity and Monitoring of Immunosuppressive Therapy Used in Systemic Autoimmune Diseases. Clinics in Chest Medicine 31:3, 565-588
CrossRef57
G. Dückers, T. Niehues. (2010) Die Bedeutung von Biologika bei der Therapie der SoJIA (Morbus Still). Zeitschrift für Rheumatologie 69:6, 505-515
CrossRef58
Gabriele Simonini, Luca Cantarini, Cecilia Bresci, Monica Lorusso, Mauro Galeazzi, Rolando Cimaz. (2010) Current therapeutic approaches to autoimmune chronic uveitis in children. Autoimmunity Reviews 9:10, 674-683
CrossRef59
G. Horneff. (2010) Malignome und Tumor-Nekrose-Faktor-Inhibitoren bei der juvenilen idiopathischen Arthritis. Zeitschrift für Rheumatologie 69:6, 516-526
CrossRef60
David C. Wilson, Anthony D. Marinov, Harry C. Blair, Daniel S. Bushnell, Susan D. Thompson, Yury Chaly, Raphael Hirsch. (2010) Follistatin-like protein 1 is a mesenchyme-derived inflammatory protein and may represent a biomarker for systemic-onset juvenile rheumatoid arthritis. Arthritis & Rheumatism 62:8, 2510-2516
CrossRef61
Robert B. Nussenblatt, Bibiana Bielekova, Richard Childs, Alan Krensky, Warren Strober, Giorgio Trinchieri, . (2010) National Institutes of Health Center for Human Immunology Conference, September 2009. Annals of the New York Academy of Sciences 1200, E1-E23
CrossRef62
Kimberly Morishita, Ross Petty, Robyn Cairns, Roxana Bolaria, David Cabral, Stuart Turvey. (2010) Serious musculoskeletal infections in children receiving anti-tumor necrosis factor-α therapy: a case series. Clinical Rheumatology 29:6, 677-681
CrossRef63
Nicolino Ruperto, Daniel J. Lovell, Pierre Quartier, Eliana Paz, Nadina Rubio-Pérez, Clovis A. Silva, Carlos Abud-Mendoza, Ruben Burgos-Vargas, Valeria Gerloni, Jose A. Melo-Gomes, Claudia Saad-Magalhães, J. Chavez-Corrales, Christian Huemer, Alan Kivitz, Francisco J. Blanco, Ivan Foeldvari, Michael Hofer, Gerd Horneff, Hans-Iko Huppertz, Chantal Job-Deslandre, Anna Loy, Kirsten Minden, Marilynn Punaro, Alejandro Flores Nunez, Leonard H. Sigal, Alan J. Block, Marleen Nys, Alberto Martini, Edward H. Giannini. (2010) Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis & Rheumatism 62:6, 1792-1802
CrossRef64
Maria Beatrice Damasio, Clara Malattia, Alberto Martini, Paolo Tomà. (2010) Synovial and inflammatory diseases in childhood: role of new imaging modalities in the assessment of patients with juvenile idiopathic arthritis. Pediatric Radiology 40:6, 985-998
CrossRef65
Jelena Basic, Dusica Pavlovic, Tatjana Jevtovic-Stoimenov, Jelena Vojinovic, Gordana Susic, Ivana Stojanovic, Gordana Kocic, Vuk Milosevic, Tatjana Cvetkovic, Milena Marinkovic, Andrej Veljkovic. (2010) Etanercept reduces matrix metalloproteinase-9 level in children with polyarticular juvenile idiopathic arthritis and TNF-α-308GG genotype. Journal of Physiology and Biochemistry 66:2, 173-180
CrossRef66
Valentina Leone, Ruth Wyllie, Helen Foster. (2010) Chronic arthritis in children and adolescents. Medicine 38:4, 177-184
CrossRef67
Kiem Oen, Ciarán M. Duffy, Shirley M. L. Tse, Suzanne Ramsey, Janet Ellsworth, Gaëlle Chédeville, Anne-Laure Chetaille, Claire Saint-Cyr, David A. Cabral, Lynn R. Spiegel, Rayfel Schneider, Bianca Lang, Adam M. Huber, Paul Dancey, Earl Silverman, Alan M. Rosenberg, Bonnie Cameron, Nicole Johnson, Jean Dorval, Rosie Scuccimarri, Sarah Campillo, Ross E. Petty, Karen N. Watanabe Duffy, Gilles Boire, Elie Haddad, Kristin Houghton, Ronald Laxer, Stuart E. Turvey, Paivi Miettunen, Katherine Gross, Jaime Guzman, Susanne Benseler, Brian M. Feldman, Victor Espinosa, Rae S. M. Yeung, Lori Tucker. (2010) Early outcomes and improvement of patients with juvenile idiopathic arthritis enrolled in a Canadian multicenter inception cohort. Arthritis Care & Research 62:4, 527-536
CrossRef68
Nuray Aktay Ayaz, Erkan Demirkaya, Yelda Bilginer, Uğur Özçelik, Nazan Çobanoğlu, Nural Kiper, Nesrin Besbas, Aysin Bakkaloğlu, Seza Özen. (2010) Preventing tuberculosis in children receiving anti-tnf treatment. Clinical Rheumatology 29:4, 389-392
CrossRef69
Nádia Emi Aikawa, Jozélio Freire Carvalho, Clovis Artur Almeida Silva, Eloísa Bonfá. (2010) Immunogenicity of Anti-TNF-α Agents in Autoimmune Diseases. Clinical Reviews in Allergy & Immunology 38:2-3, 82-89
CrossRef70
Maria Natalia Tamborenea, Guillermo Tate, Eduardo Mysler, Jose Debonis, Adrian Schijedman. (2010) Prevalence of positive ppd in a cohort of rheumatoid arthritis patients. Rheumatology International 30:5, 613-616
CrossRef71
Natalie A. Wright, Caroline D.S. Piggott, Lawrence F. Eichenfield. (2010) The Role of Biologics and Other Systemic Agents in the Treatment of Pediatric Psoriasis. Seminars in Cutaneous Medicine and Surgery 29:1, 20-27
CrossRef72
C. Malattia, M. B. Damasio, C. Basso, A. Verri, F. Magnaguagno, S. Viola, M. Gattorno, A. Ravelli, P. Toma, A. Martini. (2010) Dynamic contrast-enhanced magnetic resonance imaging in the assessment of disease activity in patients with juvenile idiopathic arthritis. Rheumatology 49:1, 178-185
CrossRef73
Mary Beth F. Son, Robert P. Sundel. 2010. Juvenile Arthritis. , 70-82.
CrossRef74
Sarah Ringold, Yun Chon, Nora G. Singer. (2009) Associations between the American College of Rheumatology pediatric response measures and the continuous measures of disease activity used in adult rheumatoid arthritis: A secondary analysis of clinical trial data from children with Polyarticular-Course Juvenile Idiopathic Arthritis. Arthritis & Rheumatism 60:12, 3776-3783
CrossRef75
M. Halbig, G. Horneff. (2009) Improvement of functional ability in children with juvenile idiopathic arthritis by treatment with etanercept. Rheumatology International 30:2, 229-238
CrossRef76
Silvia Magni-Manzoni, Oscar Epis, Angelo Ravelli, Catherine Klersy, Chiara Veisconti, Stefano Lanni, Valentina Muratore, Carlo Alberto Scir
, Silvia Rossi, Carlomaurizio Montecucco. (2009) Comparison of clinical versus ultrasound-determined synovitis in juvenile idiopathic arthritis. Arthritis & Rheumatism 61:11, 1497-1504
CrossRef77
C.H. Smith, A.V. Anstey, J.N.W.N. Barker, A.D. Burden, R.J.G. Chalmers, D.A. Chandler, A.Y. Finlay, C.E.M. Griffiths, K. Jackson, N.J. McHugh, K.E. McKenna, N.J. Reynolds, A.D. Ormerod, . (2009) British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009. British Journal of Dermatology 161:5, 987-1019
CrossRef78
Claudia Macaubas, Khoa Nguyen, Diana Milojevic, Jane L. Park, Elizabeth D. Mellins. (2009) Oligoarticular and polyarticular JIA: epidemiology and pathogenesis. Nature Reviews Rheumatology 5:11, 616-626
CrossRef79
S. Ozen, C. Wallace. (2009) Editorial and introduction: new developments in paediatric rheumatic diseases. Best Practice & Research Clinical Rheumatology 23:5, 583-587
CrossRef80
Hermine I. Brunner, Angelo Ravelli. (2009) Developing outcome measures for paediatric rheumatic diseases. Best Practice & Research Clinical Rheumatology 23:5, 609-624
CrossRef81
E. H. Giannini, N. T. Ilowite, D. J. Lovell, C. A. Wallace, C. E. Rabinovich, A. Reiff, G. Higgins, B. Gottlieb, N. G. Singer, , Y. Chon, S.-L. Lin, S. W. Baumgartner. (2009) Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis & Rheumatism 60:9, 2794-2804
CrossRef82
G. Horneff, A. Ebert, S. Fitter, K. Minden, I. Foeldvari, J. Kummerle-Deschner, A. Thon, H. J. Girschick, F. Weller, H. I. Huppertz. (2009) Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis. Rheumatology 48:8, 916-919
CrossRef83
María M. Katsicas, Ricardo A. G. Russo. (2009) Use of adalimumab in patients with juvenile idiopathic arthritis refractory to etanercept and/or infliximab. Clinical Rheumatology 28:8, 985-988
CrossRef84
Lars U.W. Müller, David A. Williams. (2009) Finding the needle in the hay stack: Hematopoietic stem cells in Fanconi anemia. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 668:1-2, 141-149
CrossRef85
Bruce Strober, Emily Berger, Jennifer Cather, David Cohen, Jeffrey J. Crowley, Kenneth B. Gordon, Alice Gottlieb, Elizabeth J. Horn, Arthur F. Kavanaugh, Neal J. Korman. (2009) A series of critically challenging case scenarios in moderate to severe psoriasis: A Delphi consensus approach. Journal of the American Academy of Dermatology 61:1, S1-S46
CrossRef86
Alexandra Villa-Forte. (2009) Anticytokine therapy in non-rheumatoid arthritis indications in 2009. Current Opinion in Rheumatology 21:3, 251-255
CrossRef87
Michael Frosch, Martina Ahlmann, Thomas Vogl, Helmut Wittkowski, Nico Wulffraat, Dirk Foell, Johannes Roth. (2009) The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1β form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. Arthritis & Rheumatism 60:3, 883-891
CrossRef88
Masaaki Mori, Takuya Naruto, Tomoyuki Imagawa, Takuji Murata, Syuji Takei, Minako Tomiita, Yasuhiko Itoh, Satoshi Fujikawa, Shumpei Yokota. (2009) Methotrexate for the treatment of juvenile idiopathic arthritis: process to approval for JIA indication in Japan. Modern Rheumatology 19:1, 1-11
CrossRef89
Moana Sulpice, Chantal Job Deslandre, Pierre Quartier. (2009) Efficacy and safety of TNFα antagonist therapy in patients with juvenile spondyloarthropathies. Joint Bone Spine 76:1, 24-27
CrossRef90
Smita V. Sukhatme, Alice B. Gottlieb. (2009) Pediatric psoriasis: updates in biologic therapies. Dermatologic Therapy 22:1, 34-39
CrossRef91
C. Egla Rabinovich, Edward Fels, Joseph Shanahan, J. Marc Majure, Thomas M. Murphy. 2009. Pulmonary Manifestations of Rheumatoid Diseases. , 201-240.
CrossRef92
(2008) Adalimumab in Juvenile Rheumatoid Arthritis. New England Journal of Medicine 359:23, 2495-2497
Full Text93
Raphael Hirsch. (2008) Is long-term etanercept therapy safe and effective in patients with juvenile RA?. Nature Clinical Practice Rheumatology 4:12, 628-629
CrossRef94
G. A. Yanik, V. T. Ho, J. E. Levine, E. S. White, T. Braun, J. H. Antin, J. Whitfield, J. Custer, D. Jones, J. L. M. Ferrara, K. R. Cooke. (2008) The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. Blood 112:8, 3073-3081
CrossRef95
Katherine Anne B Marzan, Andreas Otto Reiff. (2008) Adalimumab in juvenile rheumatoid arthritis/juvenile idiopathic arthritis. Expert Review of Clinical Immunology 4:5, 549-558
CrossRef96
Lovell, Daniel J., Ruperto, Nicolino, Goodman, Steven, Reiff, Andreas, Jung, Lawrence, Jarosova, Katerina, Nemcova, Dana, Mouy, Richard, Sandborg, Christy, Bohnsack, John, Elewaut, Dirk, Foeldvari, Ivan, Gerloni, Valeria, Rovensky, Jozef, Minden, Kirsten, Vehe, Richard K., Weiner, L. Wagner, Horneff, Gerd, Huppertz, Hans-Iko, Olson, Nancy Y., Medich, John R., Carcereri-De-Prati, Roberto, McIlraith, Melissa J., Giannini, Edward H., Martini, Alberto, . (2008) Adalimumab with or without Methotrexate in Juvenile Rheumatoid Arthritis. New England Journal of Medicine 359:8, 810-820
Full Text97
Silvia Meiorin, Angela Pistorio, Angelo Ravelli, Silvia M. Iusan, Giovanni Filocamo, Lucia Trail, Sheila Oliveira, Ruben Cuttica, Graciela Espada, Maria Alessio, Dimitrina Mihaylova, Elisabetta Cortis, Alberto Martini, Nicolino Ruperto, . (2008) Validation of the Childhood Health Assessment Questionnaire in active juvenile systemic lupus erythematosus. Arthritis & Rheumatism 59:8, 1112-1119
CrossRef98
N. Tzaribachev, J. Kuemmerle-Deschner, M. Eichner, G. Horneff. (2008) Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 4 years. Rheumatology International 28:10, 1031-1034
CrossRef99
Nicolino Ruperto, Daniel J Lovell, Pierre Quartier, Eliana Paz, Nadina Rubio-Pérez, Clovis A Silva, Carlos Abud-Mendoza, Ruben Burgos-Vargas, Valeria Gerloni, Jose A Melo-Gomes, Claudia Saad-Magalhães, Flavio Sztajnbok, Claudia Goldenstein-Schainberg, Morton Scheinberg, Immaculada Calvo Penades, Michael Fischbach, Javier Orozco, Philip J Hashkes, Christine Hom, Lawrence Jung, Loredana Lepore, Sheila Oliveira, Carol A Wallace, Leonard H Sigal, Alan J Block, Allison Covucci, Alberto Martini, Edward H Giannini. (2008) Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. The Lancet 372:9636, 383-391
CrossRef100
Jung Im NA, Jun Hyung KIM, Kyoung Chan PARK, Sang Woong YOUN. (2008) Low-dose etanercept therapy in moderate to severe psoriasis in Korean. The Journal of Dermatology 35:8, 484-490
CrossRef101
Nicolino Ruperto, Alberto Martini. (2008) Network in pediatric rheumatology: the example of the Pediatric Rheumatology International Trials Organization. World Journal of Pediatrics 4:3, 186-191
CrossRef102
Kira Michalova, Lyndell Lim. (2008) Biologic agents in the management of inflammatory eye diseases. Current Allergy and Asthma Reports 8:4, 339-347
CrossRef103
William P. Madigan, William R. Raymond, Keith J. Wroblewski, Nuthida Thebpatiphat, Richard H. Birdsong, Mohamad S. Jaafar. (2008) A Review of Pediatric Uveitis: Part Ii. Autoimmune Diseases and Treatment Modalities. Journal of Pediatric Ophthalmology & Strabismus 45:4, 202-219
CrossRef104
Jeremy Sugarman, Clifton O Bingham. (2008) Ethical issues in rheumatology clinical trials. Nature Clinical Practice Rheumatology
CrossRef105
Rolando Cimaz, Anne Marie Prieur. (2008) Advances in pediatric rheumatology. Future Rheumatology 3:3, 239-251
CrossRef106
A. Holl-Wieden, M. Beer, A. Marx, R. Bonfig, D. Tappe, H. J. Girschick. (2008) Infection of an urachal cyst during etanercept therapy in juvenile idiopathic arthritis. Rheumatology International 28:8, 819-822
CrossRef107
S. T. A. Roord, W. de Jager, L. Boon, N. Wulffraat, A. Martens, B. Prakken, F. van Wijk. (2008) Autologous bone marrow transplantation in autoimmune arthritis restores immune homeostasis through CD4+CD25+Foxp3+ regulatory T cells. Blood 111:10, 5233-5241
CrossRef108
Daniel J. Lovell, Andreas Reiff, Norman T. Ilowite, Carol A. Wallace, Yun Chon, Shao-Lee Lin, Scott W. Baumgartner, Edward H. Giannini, . (2008) Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis & Rheumatism 58:5, 1496-1504
CrossRef109
F. H. M. Prince, I. S. Ferket, S. Kamphuis, W. Armbrust, R. ten Cate, E. P. A. H. Hoppenreijs, Y. Koopman-Keemink, M. A. J. van Rossum, M. van Santen-Hoeufft, M. Twilt, L. W. A. van Suijlekom-Smit. (2008) Development of a web-based register for the Dutch national study on biologicals in JIA: www.ABC-register.nl. Rheumatology 47:9, 1413-1416
CrossRef110
Ioannis Mavrikakis, Vasilis S Liarakos, Ioannis Vergados, Jack Rootman. (2008) Orbital sarcoid treatment. Expert Review of Ophthalmology 3:2, 219-227
CrossRef111
Nicolino Ruperto, Silvia Meiorin, Silvia Mirela Iusan, Angelo Ravelli, Angela Pistorio, Alberto Martini. (2008) Consensus procedures and their role in pediatric rheumatology. Current Rheumatology Reports 10:2, 142-146
CrossRef112
Y Shirota, GG Illei, NP Nikolov. (2008) Biologic treatments for systemic rheumatic diseases. Oral Diseases 14:3, 206-216
CrossRef113
Yasuhito Nerome, Hiroyuki Imanaka, Yukiko Nonaka, Yumiko Tsuru, Nobuaki Maeno, Tomoko Takezaki, Hirosumi Mori, Harumi Akaike, Tomohiro Kubota, Yoshifumi Kawano, Syuji Takei. (2008) A case of planned pregnancy with an interruption in infliximab administration in a 27-year-old female patient with rheumatoid-factor-positive polyarthritis juvenile idiopathic arthritis which improved after restarting infliximab and methotrexate. Modern Rheumatology 18:2, 189-192
CrossRef114
Steven Yeh, Lisa J. Faia, Robert B. Nussenblatt. (2008) Advances in the diagnosis and immunotherapy for ocular inflammatory disease. Seminars in Immunopathology 30:2, 145-164
CrossRef115
Nicolino Ruperto, Alberto Martini, Daniel J. Lovell, Edward H. Giannini. (2008) Performing trials in children with rheumatic diseases: Comment on the editorial by Lehman. Arthritis & Rheumatism 58:4, 1201-1202
CrossRef116
Tim Bongartz. (2008) Tocilizumab for rheumatoid and juvenile idiopathic arthritis. The Lancet 371:9617, 961-963
CrossRef117
Shumpei Yokota, Tomoyuki Imagawa, Masaaki Mori, Takako Miyamae, Yukoh Aihara, Shuji Takei, Naomi Iwata, Hiroaki Umebayashi, Takuji Murata, Mari Miyoshi, Minako Tomiita, Norihiro Nishimoto, Tadamitsu Kishimoto. (2008) Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. The Lancet 371:9617, 998-1006
CrossRef118
(2008) Psychiatric Disorders with Anti-TNFalpha Treatment: An Adverse Drug Reaction to Keep in Mind. Drug Safety 31:10, 885-960
CrossRef119
Jan Lin, David Ziring, Sheetal Desai, Sungjin Kim, Maida Wong, Yael Korin, Jonathan Braun, Elaine Reed, David Gjertson, Ram Raj Singh. (2008) TNFα blockade in human diseases: An overview of efficacy and safety. Clinical Immunology 126:1, 13-30
CrossRef120
Shumpei YOKOTA. (2008) Interleukin-6 as a Pathogenic Factor of Systemic-onset Juvenile Idiopathic Arthritis. Japanese Journal of Clinical Immunology 31:2, 99-103
CrossRef121
Angelo Ravelli, Alberto Martini. 2008. Juvenile idiopathic arthritis. , 789-801.
CrossRef122
Yasuhito Nerome, Hiroyuki Imanaka, Yukiko Nonaka, Syuji Takei. (2007) Switching the therapy from etanercept to infliximab in a child with rheumatoid factor positive polyarticular juvenile idiopathic arthritis. Modern Rheumatology 17:6, 526-528
CrossRef123
Gerald Gartlehner, Richard A. Hansen, Beth L. Jonas, Patricia Thieda, Kathleen N. Lohr. (2007) Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence. Clinical Rheumatology 27:1, 67-76
CrossRef124
Jasmin B. Kuemmerle-Deschner, Gerd Horneff. (2007) Safety and efficacy of once-weekly application of Etanercept in children with juvenile idiopathic arthritis. Rheumatology International 28:2, 153-156
CrossRef125
Shumpei Yokota, Masaaki Mori, Tomoyuki Imagawa, Syuji Takei, Takuji Murata, Minako Tomiita, Yasuhiko Ito, Satoshi Fujikawa. (2007) Proposal for juvenile idiopathic arthritis guidance on diagnosis and treatment for primary care pediatricians and nonpediatric rheumatologists (2007). Modern Rheumatology 17:5, 353-363
CrossRef126
Riva Brik, Vardit Gepstein, Eli Shahar, Dorit Goldsher, Drora Berkovitz. (2007) Tumor necrosis factor blockade in the management of children with orphan diseases. Clinical Rheumatology 26:10, 1783-1785
CrossRef127
Nicolino Ruperto, Daniel J. Lovell, Ruben Cuttica, Nick Wilkinson, Patricia Woo, Graciela Espada, Carine Wouters, Earl D. Silverman, Zsolt Balogh, Michael Henrickson, Maria-Teresa Apaz, Eileen Baildam, Anders Fasth, Valeria Gerloni, Pekka Lahdenne, Anne-Marie Prieur, Angelo Ravelli, Rotraud K. Saurenmann, Maria Luz Gamir, Nico Wulffraat, Laszlo Marodi, Ross E. Petty, Rik Joos, Francesco Zulian, Deborah McCurdy, Barry L. Myones, Kalman Nagy, Peter Reuman, Ilona Szer, Suzanne Travers, Anna Beutler, Greg Keenan, Jason Clark, Sudha Visvanathan, Adedigbo Fasanmade, Aparna Raychaudhuri, Alan Mendelsohn, Alberto Martini, Edward H. Giannini, , . (2007) A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis & Rheumatism 56:9, 3096-3106
CrossRef128
Steven Yeh, Robert B Nussenblatt, Grace A Levy-Clarke. (2007) Emerging biologics in the treatment of uveitis. Expert Review of Clinical Immunology 3:5, 781-796
CrossRef129
Angelo Ravelli, Maka Ioseliani, Ximena Norambuena, Juliana Sato, Angela Pistorio, Federica Rossi, Nicolino Ruperto, Silvia Magni-Manzoni, Nicola Ullmann, Alberto Martini. (2007) Adapted versions of the Sharp/van der Heijde score are reliable and valid for assessment of radiographic progression in juvenile idiopathic arthritis. Arthritis & Rheumatism 56:9, 3087-3095
CrossRef130
Ciarán M. Duffy. (2007) Measurement of Health Status, Functional Status, and Quality of Life in Children with Juvenile Idiopathic Arthritis: Clinical Science for the Pediatrician. Rheumatic Disease Clinics of North America 33:3, 389-402
CrossRef131
Kathleen E. Sullivan. (2007) Inflammation in Juvenile Idiopathic Arthritis. Rheumatic Disease Clinics of North America 33:3, 365-388
CrossRef132
Jennifer E. Weiss, Norman T. Ilowite. (2007) Juvenile Idiopathic Arthritis. Rheumatic Disease Clinics of North America 33:3, 441-470
CrossRef133
T Cobo-Ibáñez, E Martín-Mola. (2007) Etanercept: long-term clinical experience in rheumatoid arthritis and other arthritis. Expert Opinion on Pharmacotherapy 8:9, 1373-1397
CrossRef134
Florence Allantaz, Dorothee Stichweh, Virginia Pascual. (2007) Interleukin-1 as a therapeutic target in systemic-onset juvenile idiopathic arthritis. Future Rheumatology 2:3, 305-312
CrossRef135
C. Keith Ozaki. (2007) Cytokines and the early vein graft: Strategies to enhance durability. Journal of Vascular Surgery 45:6, A92-A98
CrossRef136
Laura J Mirkinson, Ildy M Katona. (2007) Systemic onset juvenile idiopathic arthritis: update on pathogenesis and treatment. Expert Review of Clinical Immunology 3:3, 313-321
CrossRef137
James B. Bussel, Lisa Giulino, Susan Lee, Vivek L. Patel, Christy Sandborg, E. Richard Stiehm. (2007) Update on Therapeutic Monoclonal Antibodies. Current Problems in Pediatric and Adolescent Health Care 37:4, 118-135
CrossRef138
Angela Moore, Kenneth B. Gordon, Sewon Kang, Alice Gottlieb, Bruce Freundlich, H. Amy Xia, Seth R. Stevens. (2007) A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. Journal of the American Academy of Dermatology 56:4, 598-603
CrossRef139
Anne Havemose-Poulsen, Lars Korsbæk Sørensen, Klaus Bendtzen, Palle Holmstrup. (2007) Polymorphisms Within the IL-1 Gene Cluster: Effects on Cytokine Profiles in Peripheral Blood and Whole Blood Cell Cultures of Patients With Aggressive Periodontitis, Juvenile Idiopathic Arthritis, and Rheumatoid Arthritis. Journal of Periodontology 78:3, 475-492
CrossRef140
Angelo Ravelli, Alberto Martini. (2007) Juvenile idiopathic arthritis. The Lancet 369:9563, 767-778
CrossRef141
R. K. Saurenmann, A. V. Levin, B. M. Feldman, J. B. Rose, R. M. Laxer, R. Schneider, E. D. Silverman. (2007) Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: A long-term followup study. Arthritis & Rheumatism 56:2, 647-657
CrossRef142
Ziv Sandalon, Elizabeth M Bruckheimer, Kurt H Lustig, Haim Burstein. (2007) Long-term Suppression of Experimental Arthritis Following Intramuscular Administration of a Pseudotyped AAV2/1-TNFR:Fc Vector. Molecular Therapy 15:2, 264-269
CrossRef143
Jung-Soo Song. (2007) Review of Tumor Necrosis Factor Inhibitors on Rheumatoid Arthritis. The Journal of the Korean Rheumatism Association 14:1, 1
CrossRef144
Roy Fleischmann, Imran Iqbal. (2007) Risk???:???Benefit Profile of Etanercept in??Elderly Patients with Rheumatoid Arthritis, Ankylosing Spondylitis or??Psoriatic Arthritis. Drugs & Aging 24:3, 239-254
CrossRef145
GERD HORNEFF,, MICHAEL BORTE,, PETER MATZEN, WOLFGANG HIRSCH. 2007. Rheumatische Krankheiten und Arthropathie bei Hämophilie. , 401-435.
CrossRef146
Bridgette Guthrie, Kelly A. Rouster-Stevens, Sally L. Reynolds. (2007) Review of Medications Used in Juvenile Rheumatoid Arthritis. Pediatric Emergency Care 23:1, 38-46
CrossRef147
Pierre Quartier. (2007) When should we use TNF antagonists in children with rheumatic disease?. Joint Bone Spine 74:1, 1-3
CrossRef148
Niko K. Bender, Christoph E. Heilig, Benjamin Dröll, Jessica Wohlgemuth, Franz-Paul Armbruster, Bernhard Heilig. (2006) Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatology International 27:3, 269-274
CrossRef149
Lucienne Chatenoud. (2006) Immune therapies of autoimmune diseases: are we approaching a real cure?. Current Opinion in Immunology 18:6, 710-717
CrossRef150
ROY M. FLEISCHMANN. (2006) Comparison of the Efficacy of Biologic Therapy for Rheumatoid Arthritis: Can the Clinical Trials Be Accurately Compared?. Rheumatic Disease Clinics of North America 32, 21-28
CrossRef151
Andrea S. Doria, Raffi Karshafian, Rahim Moineddin, Arun Mohanta, Anguo Zhong, Maria Mendes, Kenneth Pritzker, Roland Jong, Peter Burns. (2006) Contrast-enhanced triggered harmonic sonography for assessment of periarticular hemodynamic changes in experimental arthritis. Pediatric Radiology 36:12, 1242-1251
CrossRef152
Philip J. Hashkes, Ronald M. Laxer. (2006) Update on the medical treatment of juvenile idiopathic arthritis. Current Rheumatology Reports 8:6, 450-458
CrossRef153
Federica Rossi, Fiorella Di Dia, Olivia Galipò, Angela Pistorio, Maura Valle, Silvia Magni-Manzoni, Nicolino Ruperto, Paolo Tomà, Alberto Martini, Angelo Ravelli. (2006) Use of the sharp and larsen scoring methods in the assessment of radiographic progression in juvenile idiopathic arthritis. Arthritis & Rheumatism 55:5, 717-723
CrossRef154
S. C. Li. (2006) Sustained Benefit from Treatment of Polyarticular Juvenile Arthritis with a Biologic Agent. AAP Grand Rounds 16:4, 38-39
CrossRef155
T. Takken, F. Eijkhof, H. Hoijtink, P. J. M. Helders, J. Net. (2006) Examining the psychometric characteristics of the Dutch childhood health assessment questionnaire: room for improvement?. Rheumatology International 26:11, 979-983
CrossRef156
Alison Jordan, Janet E. McDonagh. (2006) Juvenile idiopathic arthritis: the paediatric perspective. Pediatric Radiology 36:8, 734-742
CrossRef157
Chong-Hyeon YOON, Ho-Youn KIM. (2006) Extended indications for anti-tumor necrosis factor-α therapy. APLAR Journal of Rheumatology 9:2, 193-199
CrossRef158
(2006) Consensus on the use and monitoring of anti-TNF-α therapies for rheumatic diseases in Hong Kong 2005. APLAR Journal of Rheumatology 9:2, 175-180
CrossRef159
Daniel J. Lovell, Andreas Reiff, Olcay Y. Jones, Rayfel Schneider, James Nocton, Leonard D. Stein, Abraham Gedalia, Norman T. Ilowite, Carol A. Wallace, James B. Whitmore, Barbara White, Edward H. Giannini, . (2006) Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis & Rheumatism 54:6, 1987-1994
CrossRef160
Burkhard Möller, Peter M. Villiger. (2006) Inhibition of IL-1, IL-6, and TNF-α in immune-mediated inflammatory diseases. Springer Seminars in Immunopathology 27:4, 391-408
CrossRef161
A. Lurati, I. Pontikaki, B. Teruzzi, F. Desiati, V. Gerloni, M. Gattinara, R. Cimaz, F. Fantini. (2006) A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti–tumor necrosis factor α agents. Arthritis & Rheumatism 54:5, 1602-1607
CrossRef162
L. Thirion, D. Picard, O. Mejjad, P. Courville, X. Le Loet, P. Joly. (2006) Vasculite avec ulcérations cutanées au cours de la polyarthrite rhumatoïde : traitement par anti TNFδ. Annales de Dermatologie et de Vénéréologie 133:5, 453-455
CrossRef163
Roy Fleischmann. (2006) Safety and efficacy of etanercept in the elderly. Aging Health 2:2, 189-197
CrossRef164
Carol A. Wallace. (2006) Current management of juvenile idiopathic arthritis. Best Practice & Research Clinical Rheumatology 20:2, 279-300
CrossRef165
Michaël Hofer. (2006) Spondylarthropathies in children—are they different from those in adults?. Best Practice & Research Clinical Rheumatology 20:2, 315-328
CrossRef166
Andrea T. Borchers, Carlo Selmi, Gurtej Cheema, Carl L. Keen, Yehuda Shoenfeld, M. Eric Gershwin. (2006) Juvenile idiopathic arthritis. Autoimmunity Reviews 5:4, 279-298
CrossRef167
Giorgia Martini, Francesco Zulian. (2006) Juvenile idiopathic arthritis: current and future treatment options. Expert Opinion on Pharmacotherapy 7:4, 387-399
CrossRef168
G. Horneff. (2006) Einsatz von Biologika bei der juvenilen idiopathischen Arthritis. Zeitschrift für Rheumatologie 65:2, 152-158
CrossRef169
I M de Kleer, S Albani, B J Prakken. (2006) T-cell regulation in juvenile idiopathic arthritis. Future Rheumatology 1:1, 111-119
CrossRef170
M. Papoutsaki, A. Costanzo, A. Mazzotta, T. Gramiccia, R. Soda, S. Chimenti. (2006) Etanercept for the treatment of severe childhood psoriasis. British Journal of Dermatology 154:1, 181-183
CrossRef171
Amy L. Woodward, Robert P. Sundel. 2006. Inflammatory Diseases of the Knee: Juvenile Rheumatoid Arthritis and Lyme Disease. , 461-472.
CrossRef172
Aimee C. Hawrot, Denise W. Metry, Amy J. Theos, Moise L. Levy. (2006) Etanercept for Psoriasis in the Pediatric Population: Experience in Nine Patients. Pediatric Dermatology 23:1, 67-71
CrossRef173
Kenneth B. Gordon, Alice B. Gottlieb, Craig L. Leonardi, Boni E. Elewski, Andrea Wang, Angelika Jahreis, Ralph Zitnik. (2006) Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy. Journal of Dermatological Treatment 17:1, 9-17
CrossRef174
Masaaki Mori, Syuji Takei, Tomoyuki Imagawa, Hiroyuki Imanaka, Nobuaki Maeno, Rumiko Kurosawa, Yoshifumi Kawano, Shumpei Yokota. (2005) Pharmacokinetics, efficacy, and safety of short-term (12 weeks) etanercept for methotrexate-refractory polyarticular juvenile idiopathic arthritis in Japan. Modern Rheumatology 15:6, 397-404
CrossRef175
J. Sautner, B. F. Leeb. (2005) Moderne antirheumatische Pharmakotherapie. Der Internist 46:12, 1399-1404
CrossRef176
Anne Havemose-Poulsen, Lars Korsbæk Sørensen, Kaj Stoltze, Klaus Bendtzen, Palle Holmstrup. (2005) Cytokine Profiles in Peripheral Blood and Whole Blood Cell Cultures Associated With Aggressive Periodontitis, Juvenile Idiopathic Arthritis, and Rheumatoid Arthritis. Journal of Periodontology 76:12, 2276-2285
CrossRef177
A SPARSA. (2005) Etanercept. Annales de Dermatologie et de Vénéréologie 132:11, 861-876
CrossRef178
JANE G. SCHALLER. (2005) The History of Pediatric Rheumatology. Pediatric Research 58:5, 997-1007
CrossRef179
Vance W. Berger. 2005. Block Random Assignment. .
CrossRef180
Thomas G. Mason, Ann M. Reed. (2005) Update in juvenile rheumatoid arthritis. Arthritis & Rheumatism 53:5, 796-799
CrossRef181
Gaëlle Chédeville, Pierre Quartier, Marta Miranda, Raja Brauner, Anne-Marie Prieur. (2005) Improvements in growth parameters in children with juvenile idiopathic arthritis associated with the effect of methotrexate on disease activity. Joint Bone Spine 72:5, 392-396
CrossRef182
Marion A. J. van Rossum, Maarten Boers, Aeilko H. Zwinderman, Renée M. van Soesbergen, Helen Wieringa, Theo J. W. Fiselier, Marcel J. A. M. Franssen, Rebecca ten Cate, Lisette W. A. van Suijlekom-Smit, Nico M. Wulffraat, Wilma H. J. van Luijk, Johanna C. M. Oostveen, Wietse Kuis, Ben A. C. Dijkmans, . (2005) Development of a standardized method of assessment of radiographs and radiographic change in juvenile idiopathic arthritis: Introduction of the Dijkstra composite score. Arthritis & Rheumatism 52:9, 2865-2872
CrossRef183
Mathias Grunke, Joachim Robert Kalden. (2005) Etanercept: an introduction. Expert Review of Clinical Immunology 1:3, 313-323
CrossRef184
Alexa Adams, Thomas J.A Lehman. (2005) Update on the pathogenesis and treatment of systemic onset juvenile rheumatoid arthritis. Current Opinion in Rheumatology 17:5, 612-616
CrossRef185
J GARCIALECHUZMOYA. (2005) Complicaciones infecciosas asociadas al uso de fármacos antagonistas del factor de necrosis tumoral. Revisión de conjunto. Enfermedades Infecciosas y Microbiología Clínica 23:9, 551-559
CrossRef186
David J. Rychly, Joseph T. DiPiro. (2005) Infections Associated with Tumor Necrosis Factor-α Antagonists. Pharmacotherapy 25:9, 1181-1192
CrossRef187
H. U. Scherer, G. R. Burmester. (2005) Rheumatologie. Der Internist 46:8, 882-891
CrossRef188
Shirley M. L. Tse, Ruben Burgos-Vargas, Ronald M. Laxer. (2005) Anti-tumor necrosis factor α blockade in the treatment of juvenile spondylarthropathy. Arthritis & Rheumatism 52:7, 2103-2108
CrossRef189
John H. Chang, Peter J. McCluskey, Denis Wakefield. (2005) Acute Anterior Uveitis and HLA-B27. Survey of Ophthalmology 50:4, 364-388
CrossRef190
G. Horneff. (2005) Stellenwert der neuen Biologicals und Zytokinantagonisten in der Therapie der juvenilen idiopathischen Arthritis (JIA). Zeitschrift für Rheumatologie 64:5, 317-326
CrossRef191
C. Sengler, R. Keitzer, U. Pleyer. (2005) Uveitis bei rheumatologischen Erkrankungen im Kindesalter. Der Ophthalmologe 102:5, 463-476
CrossRef192
G. Horneff. (2005) Einsatz von Biologika bei der juvenilen idiopathischen Arthritis. Monatsschrift Kinderheilkunde 153:5, 473-479
CrossRef193
Silverman, Earl, Mouy, Richard, Spiegel, Lynn, Jung, Lawrence K., Saurenmann, Rotraud K., Lahdenne, Pekka, Horneff, Gerd, Calvo, Immaculada, Szer, Ilona S., Simpson, Karen, Stewart, John A., Strand, Vibeke, . (2005) Leflunomide or Methotrexate for Juvenile Rheumatoid Arthritis. New England Journal of Medicine 352:16, 1655-1666
Full Text194
Boulos Haraoui. (2005) Differentiating the efficacy of the tumor necrosis factor inhibitors. Seminars in Arthritis and Rheumatism 34:5, 7-11
CrossRef195
K SULLIVAN. (2005) Inflammation in Juvenile Idiopathic Arthritis. Pediatric Clinics of North America 52:2, 335-357
CrossRef196
N M Wulffraat, B Vastert, A Tyndall. (2005) Treatment of refractory autoimmune diseases with autologous stem cell transplantation: focus on juvenile idiopathic arthritis. Bone Marrow Transplantation 35, S27-S29
CrossRef197
C.M. González Fernández, J. Vázquez Pérez-Coleman, M. Montoro Álvarez, L. Carreño Pérez. (2005) Tratamiento biológico de las enfermedades reumáticas. Medicine - Programa de Formación Médica Continuada Acreditado 9:28, 1830-1839
CrossRef198
Janine A. Smith, Darby J. S. Thompson, Scott M. Whitcup, Eric Suhler, Grace Clarke, Susan Smith, Michael Robinson, Jonghyeon Kim, Karyl S. Barron. (2005) A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis & Rheumatism 53:1, 18-23
CrossRef199
Valeria Gerloni, Irene Pontikaki, Maurizio Gattinara, Francesca Desiati, Elide Lupi, Alfredomaria Lurati, Alessandra Salmaso, Flavio Fantini. (2005) Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor ? monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: Results of an open-label prospective study. Arthritis & Rheumatism 52:2, 548-553
CrossRef200
R. E. Hough, J. A. Snowden, N. M. Wulffraat. (2005) Haemopoietic stem cell transplantation in autoimmune diseases: a European perspective. British Journal of Haematology 128:4, 432-459
CrossRef201
Esi M. DeWitt, David D. Sherry, Randy Q. Cron. (2005) Pediatric Rheumatology for the Adult Rheumatologist I. JCR: Journal of Clinical Rheumatology 11:1, 21-33
CrossRef202
Earl Silverman, Lynn Spiegel, David Hawkins, Ross Petty, Donald Goldsmith, Laura Schanberg, Ciaran Duffy, Paul Howard, Vibeke Strand. (2005) Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis. Arthritis & Rheumatism 52:2, 554-562
CrossRef203
Mark G Lebwohl. (2005) Use of Etanercept in the Dermatology Setting. American Journal of Clinical Dermatology 6:1, 49-59
CrossRef204
Alice B. Gottlieb. (2005) Psoriasis: emerging therapeutic strategies. Nature Reviews Drug Discovery 4:1, 19-34
CrossRef205
DOUGLAS A. JABS, ESEN KARAMURSEL AKPEK. (2005) IMMUNOSUPPRESSION FOR POSTERIOR UVEITIS. Retina 25:1, 1-18
CrossRef206
L. Roberts, G. J. McColl. (2004) Tumour necrosis factor inhibitors: risks and benefits in patients with rheumatoid arthritis. Internal Medicine Journal 34:12, 687-693
CrossRef207
Evangelos Andreakos, Brian Foxwell, Marc Feldmann. (2004) Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation?. Immunological Reviews 202:1, 250-265
CrossRef208
Ulrika Andersson By, Edneia Tani, Ulf Andersson, Jan-Inge Henter. (2004) Tumor Necrosis Factor, Interleukin 11, and Leukemia Inhibitory Factor Produced by Langerhans Cells in Langerhans Cell Histiocytosis. Journal of Pediatric Hematology/Oncology 26:11, 706-711
CrossRef209
Dagnachew W. Workie, Bernard J. Dardzinski, T. Brent Graham, Tal Laor, Wendy A. Bommer, Kendall J. O'Brien. (2004) Quantification of dynamic contrast-enhanced MR imaging of the knee in children with juvenile rheumatoid arthritis based on pharmacokinetic modeling. Magnetic Resonance Imaging 22:9, 1201-1210
CrossRef210
Daniel J. Lovell, Theoklis E. Zaoutis, Kathleen Sullivan. (2004) Immunosuppressants, infection, and inflammation. Clinical Immunology 113:2, 137-139
CrossRef211
Debra Lewkowicz, Alice B. Gottlieb. (2004) Pediatric psoriasis and psoriatic arthritis. Dermatologic Therapy 17:5, 364-375
CrossRef212
Andrew D Cook, Kumar Visvanathan. (2004) Molecular targets in immune-mediated diseases: focus on rheumatoid arthritis. Expert Opinion on Therapeutic Targets 8:5, 375-390
CrossRef213
Robert P. Baughman. (2004) Pulmonary sarcoidosis. Clinics in Chest Medicine 25:3, 521-530
CrossRef214
Roy Fleischmann, Richard Stern, Imran Iqbal. (2004) Etanercept – review of efficacy and safety after five years of clinical use. Therapy 1:1, 11-23
CrossRef215
Nicolino Ruperto, Alberto Martini. (2004) International research networks in pediatric rheumatology: the PRINTO perspective. Current Opinion in Rheumatology 16:5, 566-570
CrossRef216
Nora G Singer, Lisabeth V Scalzi. (2004) Remittive agents in pediatric rheumatology. Current Opinion in Rheumatology 16:5, 571-576
CrossRef217
G. R. Smith, K. E. Tymms, M. Falk. (2004) Etanercept treatment of renal amyloidosis complicating rheumatoid arthritis. Internal Medicine Journal 34:9-10, 570-572
CrossRef218
J Eugene Huffstutter, Charles W. Sienknecht. (2004) Treatment of Resistant Adult Still Disease With Infliximab. JCR: Journal of Clinical Rheumatology 10:4, 218-221
CrossRef219
Roy Fleischmann, Richard Stern, Imran Iqbal. (2004) Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis. Expert Opinion on Biological Therapy 4:8, 1333-1344
CrossRef220
F. M. Ruemmele, A-M. Prieur, C. Talbotec, O. Goulet, J. Schmitz. (2004) Development of Crohn Disease During Anti???TNF-?? Therapy in a Child With Juvenile Idiopathic Arthritis. Journal of Pediatric Gastroenterology and Nutrition 39:2, 203-206
CrossRef221
Nicolino Ruperto, Kevin J. Murray, Valeria Gerloni, Nico Wulffraat, Sheila Knupp Feitosa De Oliveira, Fernanda Falcini, Pavla Dolezalova, Maria Alessio, Ruben Burgos-Vargas, Fabrizia Corona, Richard Vesely, Helen Foster, Joyce Davidson, Francesco Zulian, Line Asplin, Eileen Baildam, Julia Garcia Consuegra, Huri Ozdogan, Rotraud Saurenmann, Rik Joos, Angela Pistorio, Pat Woo, Alberto Martini, . (2004) A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis & Rheumatism 50:7, 2191-2201
CrossRef222
Andreas Otto Reiff. (2004) Developments in the treatment of juvenile arthritis. Expert Opinion on Pharmacotherapy 5:7, 1485-1496
CrossRef223
Nico M Wulffraat, Ismee M de Kleer, Berent J Prakken, Wietse Kuis. (2004) Refractory juvenile idiopathic arthritis. Best Practice & Research Clinical Haematology 17:2, 277-289
CrossRef224
Shikha Nanda, Joan M Bathon. (2004) Etanercept: a clinical review of current and emerging indications. Expert Opinion on Pharmacotherapy 5:5, 1175-1186
CrossRef225
Mark C Genovese, Joel M Kremer. (2004) Treatment of rheumatoid arthritis with etanercept. Rheumatic Disease Clinics of North America 30:2, 311-328
CrossRef226
Dirk Foell, Helmut Wittkowski, Inga Hammerschmidt, Nico Wulffraat, Heinrike Schmeling, Michael Frosch, Gerd Horneff, Wietse Kuis, Clemens Sorg, Johannes Roth. (2004) Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations. Arthritis & Rheumatism 50:4, 1286-1295
CrossRef227
JE Munro, KJ Murray. (2004) Advances in paediatric rheumatology: Beyond NSAIDs and joint replacement. Journal of Paediatrics and Child Health 40:4, 161-169
CrossRef228
Ciaran M. Duffy. (2004) Health outcomes in pediatric rheumatic diseases. Current Opinion in Rheumatology 16:2, 102-108
CrossRef229
Verónica Pérez-Guijo, Manuel Santos-Lacomba, Margarita Sánchez-Hernández, María del Carmen Castro-Villegas, José María Gallardo-Galera, Eduardo Collantes-Estévez. (2004) Tumour necrosis factor-alpha levels in aqueous humour and serum from patients with uveitis: the involvement of HLA-B27. Current Medical Research and Opinion 20:2, 155-157
CrossRef230
William P Arend, Cem Gabay. (2004) Cytokines in the rheumatic diseases. Rheumatic Disease Clinics of North America 30:1, 41-67
CrossRef231
R. Phillip Dellinger, Joseph E. Parrillo. (2004) Mediator modulation therapy of severe sepsis and septic shock: Does it work? *. Critical Care Medicine 32:1, 282-286
CrossRef232
Sunil M Thadani, C Stephen Foster. (2004) Treatment of Ocular Inflammation in Children. Pediatric Drugs 6:5, 289-301
CrossRef233
Dinesh Khanna, Maureen McMahon, Daniel E Furst. (2004) Safety of Tumour Necrosis Factor-?? Antagonists. Drug Safety 27:5, 307-324
CrossRef234
Eric B. Suhler, Tammy M. Martin, James T. Rosenbaum. (2003) HLA-B27???associated uveitis: overview and current perspectives. Current Opinion in Ophthalmology 14:6, 378-383
CrossRef235
Silvia Magni-Manzoni, Federica Rossi, Angela Pistorio, Francesca Temporini, Stefania Viola, Giampiero Beluffi, Alberto Martini, Angelo Ravelli. (2003) Prognostic factors for radiographic progression, radiographic damage, and disability in juvenile idiopathic arthritis. Arthritis & Rheumatism 48:12, 3509-3517
CrossRef236
Brandt P. Groh. (2003) Current concepts in pediatric rheumatology. Current Opinion in Orthopaedics 14:6, 385-391
CrossRef237
Peter Chira, Christy I. Sandborg. (2003) Novel therapies in pediatric rheumatic diseases. Current Opinion in Pediatrics 15:6, 579-585
CrossRef238
Lucila M. A. Agle, Liza B. Vazquez-Cobian, Thomas J. A. Lehman. (2003) Clinical trials in pediatric uveitis. Current Rheumatology Reports 5:6, 477-481
CrossRef239
Todd Ellerin, Robert H. Rubin, Michael E. Weinblatt. (2003) Infections and anti-tumor necrosis factor ? therapy. Arthritis & Rheumatism 48:11, 3013-3022
CrossRef240
K. BENDTZEN, P. R. HANSEN, K. RIENECK, . (2003) Spironolactone inhibits production of proinflammatory cytokines, including tumour necrosis factor-alpha and interferon-gamma, and has potential in the treatment of arthritis. Clinical and Experimental Immunology 134:1, 151-158
CrossRef241
Lynn Wimett, Gary Laustsen. (2003) TNF-α Inhibitors Offer Hope to RA Patients. The Nurse Practitioner 28:10, 40-48
CrossRef242
Ian K Campbell, Lynden J Roberts, Ian P Wicks. (2003) Molecular targets in immune-mediated diseases: the case of tumour necrosis factor and rheumatoid arthritis. Immunology and Cell Biology 81:5, 354-366
CrossRef243
Philip J Mease. (2003) Current treatment of psoriatic arthritis. Rheumatic Disease Clinics of North America 29:3, 495-511
CrossRef244
Bengt Fadeel, Jan-Inge Henter. (2003) Langerhans-cell histiocytosis: neoplasia or unbridled inflammation?. Trends in Immunology 24:8, 409-410
CrossRef245
Roy Fleischmann. (2003) Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritis. Expert Opinion on Drug Safety 2:4, 347-365
CrossRef246
Gary N Holland, E.Richard Stiehm. (2003) Special considerations in the evaluation and management of uveitis in children. American Journal of Ophthalmology 135:6, 867-878
CrossRef247
Evangelos Andreakos. (2003) Targeting cytokines in autoimmunity: new approaches, new promise. Expert Opinion on Biological Therapy 3:3, 435-447
CrossRef248
Ross E Petty, Justine R Smith, James T Rosenbaum. (2003) Arthritis and uveitis in children. American Journal of Ophthalmology 135:6, 879-884
CrossRef249
Laura E. Schanberg, Kelly K. Anthony, Karen M. Gil, Elana C. Maurin. (2003) Daily pain and symptoms in children with polyarticular arthritis. Arthritis & Rheumatism 48:5, 1390-1397
CrossRef250
Schwartz, Robert S., . (2003) Diversity of the Immune Repertoire and Immunoregulation. New England Journal of Medicine 348:11, 1017-1026
Full Text251
Helen E. Foster, Nicola Marshall, Andrea Myers, Pippa Dunkley, Ian D. Griffiths. (2003) Outcome in adults with juvenile idiopathic arthritis: A quality of life study. Arthritis & Rheumatism 48:3, 767-775
CrossRef252
C. Brousse. (2003) Les inhibiteurs du TNFα. La Revue de Médecine Interne 24:2, 123-126
CrossRef253
Allen P Anandarajah, Christopher T Ritchlin. (2003) Etanercept in psoriatic arthritis. Expert Opinion on Biological Therapy 3:1, 169-177
CrossRef254
Andreas M. Reimold. (2003) New Indications for Treatment of Chronic Inflammation by TNF-?? Blockade. The American Journal of the Medical Sciences 325:2, 75-92
CrossRef255
Barry Bresnihan, Gaye Cunnane. (2003) Infection complications associated with the use of biologic agents. Rheumatic Disease Clinics of North America 29:1, 185-202
CrossRef256
Lucila MA Agle, Margalit Rosenkranz, Thomas JA Lehman. (2003) Novel therapies for the treatment of juvenile rheumatoid arthritis (juvenile idiopathic arthritis). Expert Opinion on Investigational Drugs 12:1, 19-28
CrossRef257
Renee F Robinson, Milap C Nahata, John R Hayes, Robert Rennebohm, Gloria Higgins. (2003) Quality-of-Life Measurements in Juvenile Rheumatoid Arthritis Patients Treated with Etanercept. Clinical Drug Investigation 23:8, 511-518
CrossRef258
Robert P Baughman, Michael Iannuzzi. (2003) Tumour Necrosis Factor in Sarcoidosis and its Potential for Targeted Therapy. BioDrugs 17:6, 425-431
CrossRef259
S. Lori Brown, Mark H. Greene, Sharon K. Gershon, Evelyne T. Edwards, M. Miles Braun. (2002) Tumor necrosis factor antagonist therapy and lymphoma development: Twenty-six cases reported to the Food and Drug Administration. Arthritis & Rheumatism 46:12, 3151-3158
CrossRef260
Eleftheria Zeggini, Wendy Thomson, Dominic Kwiatkowski, Anna Richardson, William Ollier, Rachelle Donn, . (2002) Linkage and association studies of single-nucleotide polymorphism-tagged tumor necrosis factor haplotypes in juvenile oligoarthritis. Arthritis & Rheumatism 46:12, 3304-3311
CrossRef261
Nahmah Kim, Lashon Ussin, Xin Cheng, Ramachandran Murali, Kathleen E. Sullivan. (2002) TNFα Inhibition in MRL/lpr Mice Ameliorates Pulmonary but not Renal Disease. Journal of Autoimmunity 19:4, 215-222
CrossRef262
Evangelos Andreakos, Peter C Taylor, Marc Feldmann. (2002) Monoclonal antibodies in immune and inflammatory diseases. Current Opinion in Biotechnology 13:6, 615-620
CrossRef263
Sujata Sawhney. (2002) Management of juvenile idiopathic arthritis. The Indian Journal of Pediatrics 69:10, 893-897
CrossRef264
Hulya Bukulmez, Robert A. Colbert. (2002) Juvenile spondyloarthropathies and related arthritis. Current Opinion in Rheumatology 14:5, 531-535
CrossRef265
Rayfel Schneider, Murray H Passo. (2002) Juvenile rheumatoid arthritis. Rheumatic Disease Clinics of North America 28:3, 503-530
CrossRef266
Diana S Milojevic, Norman T Ilowite. (2002) Treatment of rheumatic diseases in children: special considerations. Rheumatic Disease Clinics of North America 28:3, 461-482
CrossRef267
Evangelos T Andreakos, Brian M Foxwell, Fionula M Brennan, Ravinder N Maini, Marc Feldmann. (2002) Cytokines and anti-cytokine biologicals in autoimmunity: present and future. Cytokine & Growth Factor Reviews 13:4-5, 299-313
CrossRef268
Prudence J. Manners. (2002) State of the art: Juvenile idiopathic arthritis. APLAR Journal of Rheumatology 5:1, 29-34
CrossRef269
Kevin J Murray, Daniel J Lovell. (2002) Advanced therapy for juvenile arthritis. Best Practice & Research Clinical Rheumatology 16:3, 361-378
CrossRef270
Mark C. Genovese, Joan M. Bathon, Richard W. Martin, Roy M. Fleischmann, John R. Tesser, Michael H. Schiff, Edward C. Keystone, Mary Chester Wasko, Larry W. Moreland, Arthur L. Weaver, Joseph Markenson, Grant W. Cannon, George Spencer-Green, Barbara K. Finck. (2002) Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes. Arthritis & Rheumatism 46:6, 1443-1450
CrossRef271
Joseph C. Shanahan, E.William St. Clair. (2002) Tumor Necrosis Factor-α Blockade: A Novel Therapy for Rheumatic Disease. Clinical Immunology 103:3, 231-242
CrossRef272
Apostolia-Maria Tsimberidou, Francis J Giles. (2002) TNF-α targeted therapeutic approaches in patients with hematologic malignancies. Expert Review of Anticancer Therapy 2:3, 277-286
CrossRef273
Gorman, Jennifer D., Sack, Kenneth E., Davis, John C. Jr., . (2002) Treatment of Ankylosing Spondylitis by Inhibition of Tumor Necrosis Factor α. New England Journal of Medicine 346:18, 1349-1356
Full Text274
M. Elaine Husni, Agnes L. Maier, Philip J. Mease, Steven S. Overman, Patricia Fraser, Ellen M. Gravallese, Michael E. Weinblatt. (2002) Etanercept in the treatment of adult patients with Still's disease. Arthritis & Rheumatism 46:5, 1171-1176
CrossRef275
Marc Feldmann. (2002) Timeline: Development of anti-TNF therapy for rheumatoid arthritis. Nature Reviews Immunology 2:5, 364-371
CrossRef276
Lisa G. Criscione, E. William St. Clair. (2002) Tumor necrosis factor-α antagonists for the treatment of rheumatic diseases. Current Opinion in Rheumatology 14:3, 204-211
CrossRef277
Heidi Schooltink, Stefan Rose-John. (2002) Cytokines as Therapeutic Drugs. Journal of Interferon & Cytokine Research 22:5, 505-516
CrossRef278
L.W. Moreland, R.P. Bucy, M.E. Weinblatt, K.M. Mohler, G.T. Spencer-Green, W.W. Chatham. (2002) Immune Function in Patients with Rheumatoid Arthritis Treated with Etanercept. Clinical Immunology 103:1, 13-21
CrossRef279
John K. Jenkins, Kenneth J. Hardy. (2002) Biological Modifier Therapy for the Treatment of Rheumatoid Arthritis. The American Journal of the Medical Sciences 323:4, 197-205
CrossRef280
Jaroslaw P. Maciejewski, Antonio M. Ristiano, Elaine M. Sloand, Laura Wisch, Nancy Geller, John A. Barrett, Neal S. Young. (2002) A pilot study of the recombinant soluble human tumour necrosis factor receptor (p75)-Fc fusion protein in patients with myelodysplastic syndrome. British Journal of Haematology 117:1, 119-126
CrossRef281
M.-J. Kaiser, M.-C. Bozonnat, C. Jorgensen, J.-P. Daur
CrossRef282
Cem Gabay. (2002) Cytokine inhibitors in the treatment of rheumatoid arthritis. Expert Opinion on Biological Therapy 2:2, 135-149
CrossRef283
Justine R. Smith, James T. Rosenbaum. (2002) Management of uveitis: A rheumatologic perspective. Arthritis & Rheumatism 46:2, 309-318
CrossRef284
Roy Fleischmann, Imran Iqbal, Pallavi Nandeshwar, Andres Quiceno. (2002) Safety and Efficacy of Disease-Modifying Anti-Rheumatic Agents. Drug Safety 25:3, 173-197
CrossRef285
Heinz Wiendl, Reinhard Hohlfeld. (2002) Therapeutic Approaches in Multiple Sclerosis. BioDrugs 16:3, 183-200
CrossRef286
Susan Lightman, Howesen Kok. (2002) Developments in the treatment of uveitis. Expert Opinion on Investigational Drugs 11:1, 59-67
CrossRef287
Ian C. Chikanza. (2002) Juvenile Rheumatoid Arthritis. Pediatric Drugs 4:5, 335-348
CrossRef288
Justine R. Smith. (2002) Management of Uveitis in Pediatric Patients. Pediatric Drugs 4:3, 183-189
CrossRef289
Gillian M. Keating, Blair Jarvis. (2002) Management of Rheumatoid Arthritis. Disease Management and Health Outcomes 10:1, 17-39
CrossRef290
Pere Santamaria. (2001) Effector lymphocytes in autoimmunity. Current Opinion in Immunology 13:6, 663-669
CrossRef291
Henter, Jan-Inge, Karlén, Jonas, Calming, Ulrika, Bernstrand, Cecilia, Andersson, Ulf, Fadeel, Bengt, . (2001) Successful Treatment of Langerhans'-Cell Histiocytosis with Etanercept. New England Journal of Medicine 345:21, 1577-1578
Full Text292
Visa E. A. Honkanen, Andrew F. Siegel, John Paul Szalai, Vance Berger, Brian M. Feldman, Jeffrey N. Siegel. (2001) A three-stage clinical trial design for rare disorders. Statistics in Medicine 20:20, 3009-3021
CrossRef293
Jean-Marie Reimund, Pierre Raboisson, Guillaume Pinna, Claire Lugnier, Jean-Jacques Bourguignon, Christian D. Muller. (2001) Anti-TNF-α Properties of New 9-Benzyladenine Derivatives with Selective Phosphodiesterase-4- Inhibiting Properties. Biochemical and Biophysical Research Communications 288:2, 427-434
CrossRef294
Hermine I. Brunner, Kwan N. Kim, Susan H. Ballinger, Suzanne L. Bowyer, Thomas A. Griffin, Gloria C. Higgins, Richard Mier, Murray H. Passo, Robert Rennebohm, Kenneth Schikler, Daniel J. Lovell. (2001) Current Medication Choices in Juvenile Rheumatoid Arthritis II ???Update of a Survey Performed in 1993. JCR: Journal of Clinical Rheumatology 7:5, 295-300
CrossRef295
Anne-Marie Prieur, Gaëlle Chèdeville. (2001) Prognostic factors in juvenile idiopathic arthritis. Current Rheumatology Reports 3:5, 371-378
CrossRef296
Randy Q. Cron. (2001) Treatment for JRA in the New Millennium. JCR: Journal of Clinical Rheumatology 7:5, 283-285
CrossRef297
Donald T. Kulas, Laura Schanberg. (2001) Juvenile idiopathic arthritis. Current Opinion in Rheumatology 13:5, 392-398
CrossRef298
Peter J. Weis, Paul J. DeMarco, Ken D. Pischel. (2001) Can Parvovirus B19 Infection Trigger Adult Still???s Disease? Report of a Case Controlled with Infliximab. JCR: Journal of Clinical Rheumatology 7:4, 277-279
CrossRef299
Alan Stern, Roger Riley, Lenore Buckley. (2001) Worsening of Macrophage Activation Syndrome in a Patient with Adult Onset Still???s Disease after Initiation of Etanercept Therapy. JCR: Journal of Clinical Rheumatology 7:4, 252-256
CrossRef300
Jennifer Hamilton, Hilary Capell. (2001) The treatment of juvenile arthritis. Expert Opinion on Pharmacotherapy 2:7, 1085-1092
CrossRef301
Justine R. Smith, Ralph D. Levinson, Gary N. Holland, Douglas A. Jabs, Michael R. Robinson, Scott M. Whitcup, James T. Rosenbaum. (2001) Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis & Rheumatism 45:3, 252-257
CrossRef302
Brian Feldman, Elaine Wang, Andrew Willan, John Paul Szalai. (2001) The randomized placebo-phase design for clinical trials. Journal of Clinical Epidemiology 54:6, 550-557
CrossRef303
Andreas Reiff, Syuji Takei, Said Sadeghi, Ann Stout, Bracha Shaham, Bram Bernstein, Kerry Gallagher, Timothy Stout. (2001) Etanercept therapy in children with treatment-resistant uveitis. Arthritis & Rheumatism 44:6, 1411-1415
CrossRef304
Peter C. Taylor. (2001) Anti–tumor necrosis factor therapies. Current Opinion in Rheumatology 13:3, 164-169
CrossRef305
Winfried B. Graninger, Josef S. Smolen. (2001) One-year inhibition of tumor necrosis factor-α: a major success or a larger puzzle?. Current Opinion in Rheumatology 13:3, 209-213
CrossRef306
Marc Feldmann, Ravinder N. Maini. (2001) A
NTI -TNFα THERAPY OF RHEUMATOID ARTHRITIS : What Have We Learned?. Annual Review of Immunology 19:1, 163-196
CrossRef307
Epstein, Franklin H., , Choy, Ernest H.S., Panayi, Gabriel S., . (2001) Cytokine Pathways and Joint Inflammation in Rheumatoid Arthritis. New England Journal of Medicine 344:12, 907-916
Full Text308
H. E. Seymour, A. Worsley, J. M. Smith, S. H. L. Thomas. (2001) Anti-TNF agents for rheumatoid arthritis. British Journal of Clinical Pharmacology 51:3, 201-208
CrossRef309
Tore K. Kvien, Till Uhlig, Ivar S??nb?? Kristiansen. (2001) Criteria for TNF-Targeted Therapy in Rheumatoid Arthritis. Drugs 61:12, 1711-1720
CrossRef310
Laura B. Hughes, Larry W. Moreland. (2001) New Therapeutic Approaches to the Management of Rheumatoid Arthritis. BioDrugs 15:6, 379-393
CrossRef311
Sherine E. Gabriel, Douglas Coyle, Larry W. Moreland. (2001) A Clinical and Economic Review of Disease-Modifying Antirheumatic Drugs. PharmacoEconomics 19:7, 715-728
CrossRef312
Gabor G Illei, Peter E Lipsky. (2000) Novel, non-antigen-specific therapeutic approaches to autoimmune/inflammatory diseases. Current Opinion in Immunology 12:6, 712-718
CrossRef313
Charles E Egwuagu, Janine A Smith. (2000) Uveitis. Expert Opinion on Therapeutic Targets 4:6, 715-733
CrossRef314
Ian C Chikanza, Lazaros I Sakkas. (2000) Advances in the therapy of rheumatoid arthritis with biological agents. Expert Opinion on Emerging Drugs 5:4, 367-384
CrossRef315
Matthias D. Becker, James T. Rosenbaum. (2000) Current and future trends in the use of immunosuppressive agents in patients with uveitis. Current Opinion in Opthalmology 11:6, 472-477
CrossRef316
Klippel, John H., . (2000) Biologic Therapy for Rheumatoid Arthritis. New England Journal of Medicine 343:22, 1640-1641
Full Text317
Bathon, Joan M., Martin, Richard W., Fleischmann, Roy M., Tesser, John R., Schiff, Michael H., Keystone, Edward C., Genovese, Mark C., Wasko, Mary Chester, Moreland, Larry W., Weaver, Arthur L., Markenson, Joseph, Finck, Barbara K., . (2000) A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis. New England Journal of Medicine 343:22, 1586-1593
Full Text318
Bradley J. Bloom. (2000) Development of diabetes mellitus during etanercept therapy in a child with systemic-onset juvenile rheumatoid arthritis. Arthritis & Rheumatism 43:11, 2606-2608
CrossRef319
Anne-Marie Prieur, Pierre Quartier. (2000) Comparative Tolerability of Treatments for Juvenile Idiopathic Arthritis. BioDrugs 14:3, 159-183
CrossRef320
Charles B. Cairns, Edward A. Panacek, Alden H. Harken, Anirban Banerjee. (2000) Bench to Bedside Tumor Necrosis Factor-alpha: From Inflammation to Resuscitation. Academic Emergency Medicine 7:8, 930-941
CrossRef321
Thaschawee Arkachaisri, Thomas J. A. Lehman. (2000) Use of biologics in the treatment of childhood rheumatic diseases. Current Rheumatology Reports 2:4, 330-336
CrossRef322
Nico M. Wulffraat, Lieke AM Sanders, Wietse Kuis. (2000) Autologous hemopoietic stem-cell transplantation for children with refractory autoimmune disease. Current Rheumatology Reports 2:4, 316-323
CrossRef323
Stehle, Rogers, Harmsen, Ezekowitz. (2000) A Soluble Mannose Receptor Immunoadhesin Enhances Phagocytosis of Pneumocystis carinii by Human Polymorphonuclear Leukocytes In Vitro. Scandinavian Journal of Immunology 52:2, 131-137
CrossRef324
Nancy L. Carteron. (2000) Cytokines in rheumatoid arthritis: trials and tribulations. Molecular Medicine Today 6:8, 315-323
CrossRef325
Fabrizio De Benedetti, Angelo Ravelli. (2000) Juvenile Idiopathic Arthritis. BioDrugs 14:2, 93-98
CrossRef326
Hanns-Martin Lorenz. (2000) Biological agents: a novel approach to the therapy of rheumatoid arthritis. Expert Opinion on Investigational Drugs 9:7, 1479-1490
CrossRef327
David D. Sherry. (2000) What's New in the Diagnosis and Treatment of Juvenile Rheumatoid Arthritis. Journal of Pediatric Orthopaedics 20:4, 419-420
CrossRef328
David Sherry. (2000) Journal of Pediatric Orthopedics 20:4, 419-420
CrossRef329
Pisetsky, David S., . (2000) Tumor Necrosis Factor Blockers in Rheumatoid Arthritis. New England Journal of Medicine 342:11, 810-811
Full Text330
&NA;. (2000) Etanercept: new era of treatment for juvenile RA. Inpharma Weekly &NA;:1230, 15
CrossRef
